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Colorectal cancer is the third most common cancer and cause of death due to 
cancer in the United States.  Death due to colorectal cancer is generally caused by 
hepatic metastasis rather than the primary tumor itself.  The five-year survival rate is 
only 10% for patients whose colorectal cancer metastasized, which indicates the need for 
more effective therapies to treat colon cancer.  The diet contains (1) preformed vitamin 
A as retinyl esters in animal-derived food sources and (2) provitamin A carotenoids in 
plant-derived food sources.  Once absorbed, retinol is re-esterified and transported to the 
liver, the major site of vitamin A storage.  Therefore, dietary vitamin A supplementation 
can increase retinol levels in the colon and liver, potentially affecting both primary colon 
tumors and liver metastases of the primary tumors. 
All-trans–retinoic acid (ATRA) is thought to regulate most of the effects of 
retinoids, via the ATRA/RAR/RARE pathway exerting an inhibitory effect on cancer 
growth and progression.  As cancer progresses, colon cancer acquires the resistance to 
 vi
ATRA.  The purpose of this study is to understand the mechanism by which retinol 
decreased the growth and progression of ATRA-resistant human colon cancer in vivo and 
in vitro.  We first demonstrated that retinol decreased the growth of ATRA-resistant 
colon cancer cells by arresting cell cycle progression independent of the 
ATRA/RAR/RARE pathway.  Next, we showed retinol inhibited ATRA-resistant 
human colon cancer cell invasion by decreasing MMP-2, -9 and PI3K activity in vitro.  
Finally, dietary vitamin A supplementation decreased the incidence and multiplicity of 
liver metastases in nude mice intrasplenically injected with ATRA-resistant human colon 
cancer cells.  Taken together, these data suggest the possibility of dietary vitamin A 
supplementation for colon cancer therapy and prevention. 
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Chapter 1:  Introduction 
1. COLORECTAL CANCER 
1.1. Colorectal Cancer General Overview 
Colorectal cancer is the third most common cancer and cause of death due to 
cancer in the United States.  In 2007, an estimated 153,760 new cases are expected to be 
diagnosed, and 52,180 deaths from colorectal cancer are predicted to occur in 2007 (1).  
Genetic alterations are associated with colon carcinogenesis (Figure 1.1).  Generally, 
five to seven deleterious genetic alterations occur when a normal epithelial cell becomes 
a carcinoma.  There are two key pathways by which these genetic alterations can result 
in colon cancer: (1) chromosomal instability (CIN) and (2) microsatellite instability 
(MSI).  About 85% of colorectal cancers are due to CIN and the remaining 15% are due 
to MSI (2).  Colon cancer caused by CIN contains a variety of changes in chromosome 
number.  It includes deleterious losses at chromosome 5q, chromosome 18q, and 
chromosome 17p.  KRAS, Adenomatous Polyposis Coli (APC) (5q), 
DCC/MADH2/MADH4 (18q), and TP53 (17p) are important genes on these 
chromosomes.  For example, the loss of APC is the first step in the colon cancer 
progression pathway.  The APC gene, located on chromosome 5q, plays an important 
role in cell adhesion and signal transduction by regulating β-catenin degradation (3).  
Moreover, it is a tumor suppressor gene (4).  The mutations of the APC gene include 
insertions, deletions, and nonsense mutations which can cause frame shifts and premature 
stop codons and are associated with Familial Adenomaceous Polyposis Coli (FAP) (5).  
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Colorectal cancer caused by MSI includes a series of defects in the DNA 
mismatch-repair genes.  The mutations of the tumor suppressor genes as well as DNA 
mismatch-repair genes also lead to the transition from a normal cell into a tumor cell.  
Specifically, these mutations are associated with hereditary nonpolyposis colorectal 
cancer (HNPCC).  These DNA repair genes include hMSH2 (human mutS homolog 2) 
on chromosome 2p16, hMLH1 (human mutL homolog 1) on chromosome 3p21, PMS2 
(postmeiotic segregation 2) on chromosome 7p22, and hMSH6 on chromosome 2p16.   
Risk of colon cancer increases with age.  More than 90% of cases are diagnosed 
in people older than 50.  The risk is also increased by certain acquired or inherited 
mutations as mentioned above, a personal or family history of colon cancer and polyps, 
or a personal history of inflammatory bowel disease.  Several modifiable factors are 
associated with increased risk of colon cancer.  These include obesity, physical 
inactivity, smoking, heavy alcohol consumption, a diet high in red or processed meat, and 
insufficient intake of fruits and vegetables (6).  
 
1.2. Colon Cancer Metastasis 
Five year survival rate for patients with colorectal cancer is 64% (1).  If 
colorectal cancer is detected in early stage, the five year survival rate is 90% (1).  
However, only 39% of colorectal cancer is diagnosed at early stage because of the low 
rate of screening (1).  Death due to colorectal cancer is generally caused by hepatic 
metastasis of the primary tumor, rather than the primary tumor itself (7).  The five-year 
survival rate for colorectal cancer patients with metastasis is only 10% (1).  Metastasis 
 3
consists of several processes including: (1) invasion or digestion of the basement 
membrane by tumor cells and migration of these cells through the basement membrane 
into the circulation (intravasation) and (2) migration of the cells out of the circulation and 
invasion into the target tissue (extravasation).  Colorectal cancer is rated using Duke’s 
classification system that contains four stages: A to D.  Duke’s stage A refers to tumors 
that affect only the mucosa of the bowel and not other structures of the colon.  Duke’s 
stage B indicates the tumor has invaded into or through the muscularis propria of the 
colon.  In Duke’s stage C the cancer has spread to the local lymph nodes.  Duke’s stage 
D indicates that the cancer has metastasized to distant tissues and organs. 
 
Metastasis and Matrixmetalloproteinases (MMPs) 
Cancer cell invasion and metastasis are multistep processes that involve 
extracellular matrix (ECM) proteolysis and changes in adhesion molecules.  Matrix 
metalloproteinases (MMPs) are family of proteolytic enzymes which degrade the ECM 
during cancer progression [For a review please see: (8,9)].  MMP overexpression has 
been linked with invasion and metastasis and inhibitiors of MMPs block invasive and 
metastatic activities of many tumor types.  MMP’s are classified into four groups based 
on their substrate; collagenases, gelatinases, stromelysins and matrilysins.  Particularly 
one group of MMPs, the gelatinases MMP-2 and –9, are associated with progression of 
colon cancer [For a review please see: (9)].  MMP-2 and -9 mRNA were elevated in 
colon cancer tissues as compared with normal colon tissues (10,11).  Protein levels and 
activation of MMP-2 and -9 in colon cancer were closely related with Duke’s staging 
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(12).  The protein levels of MMP-2 and -9 were increased in invasive regions of colon 
cancer (13).  Specifically, MMP-2 was significantly overexpressed in Duke’s D stage 
(13,14).  MMP-2 and -9 activation has also been shown to be increased in patients with 
metastases (15).  Those data indicate that MMP-2 and -9 are involved in cancer 
progression. 
 
Metastasis and Phosphatidylinositol 3-kinases (PI3K) Signaling 
Phosphatidylinositol 3-kinases (PI3Ks) catalyze the phosphorylation of the 3-OH 
position of the inositol head groups of the phosphatidylinositol (PI) lipids, 
phosphatidylinos--itol(4)phosphate [PI(4)P], and phosphatidylinositol(4,5)bisphosphate 
[PI(4,5)P2] to generate PI(3)P, PI(3,4)P2 and PI(3,4,5)P3, respectively (16).  PI(3,4)P2 
and PI(3,4,5)P3 are generally absent from resting cells, but their intracellular 
concentration rises markedly upon stimulation via a variety of cell surface receptors, 
suggesting a second messenger function.  PI3K can be classified into three main groups 
on the basis of their substrate and structure.  The class-1 PI3K is the most studied and is 
a key enzyme in a intracellular signaling pathway, modulated by many growth and 
survival factors, which regulate cell proliferation, growth, survival and apoptosis (17,18).  
In addition, the class-1 PI3K is highly expressed in colon cancer cell lines (19).  The 
class-1 PI3K is a heterodimer composed of a catalytic subunit (p110) and a regulator 
subunit (p85).  The substrate for class I PI3K is PI(4,5)P2 which generates the second 
messenger PI(3,4,5)P3.  The PI3K are also involved in cancer cell proliferation, 
survival, motility, differentiation, cytoskeletal rearrangement, and angiogenesis (20,21).  
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The PI3K gene is often overexpressed or mutated contributing to tumor progression in 
breast, colon, and several other cancers [For a review please see: (22)].  In colon cancer, 
PIK3CA, encoding the p110 subunit, is often mutated in either the kinase domain or 
helical domain to increase PI3K activity and consequently increase metastasis of colon 
cancer (23,24). 
 
1.3. Dietary Chemoprevention of Colorectal Cancer 
The five-year survival rate for colon cancer has dropped for the past 20 years 
because of improved diagnosis and treatment.  However, the five-year survival rate is 
still 10% for patients whose colorectal cancer metastasized, which indicates the need for 
more effective therapies to treat colon cancer.  Many studies have examined nutrients 
such as calcium, folate, fiber, omega-3 fatty acids, vitamin D, and vitamin A as 
prospective chemoprevention and chemotherapy agents for colorectal cancers [For a 
review please see; (25)].  Fiber has long been considered as a chemoprevention agent 
for colon cancer.  However, intervention randomized trials failed to support the inverse 
effect of fiber intake on colon cancer prevention (26).  However, the other nutrients 
mentioned above are promising in colon cancer prevention.  For example there is an 
inverse association between calcium and vitamin D intake and risk of colon cancer (27).  
Calcium and vitamin D may act together to decrease the risk of colorectal cancer, as 
vitamin D is required for the absorption of calcium.  Interestingly, folate showed two 
opposing effects depending on the stage of colon cancer.  Folate supplementation had an 
inhibitory effect on the initiation of colon cancer progression (28).  However, folate 
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deficiency reduced the size of colon cancer lesion (28).  Omega-3 fatty acids in fish oil 
protect against colon tumorigenesis in epidemiologic, preclinical and clinical studies [For 
a review please see; (29)].  In addition, the retinoids, a group of compounds consisting 
of vitamin A (retinol), its natural metabolites, and several synthetic compounds have been 
shown in numerous experimental situations to act as cancer chemopreventive and 
therapeutic agents [for review see: (30-32)].  All-trans-retinoic acid (ATRA) 
accomplishes all these activities and most studies concerning retinoids have investigated 
the mechanisms by which ATRA regulates tumor growth and progression.  However, 
tumors became ATRA-resistant as cancer progresses and the colon is exposed to retinol 
from the diet.  Therefore, we evaluated the antiproliferative, antimetastatic, potentially 




Retinol (Vitamin A), a fat-soluble vitamin, has important roles in vision, growth 
and development, immune function, and reproduction.  The chemical structure of retinol 
contains a β-ionone ring, a polyunsaturated tail, and an alcohol end group (Figure 1.2).  
The diet contains (1) preformed vitamin A as retinyl esters in animal-derived food 
sources and (2) provitamin A carotenoids in plant-derived food sources.  Retinyl esters 
are cleaved within the intestinal lumen to yield retinol (Figure 1.2).  When retinol is 
absorbed from the enterocytes, retinol is re-esterified and transported to the liver via 
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chylomicrons (33).  Retinol is de-esterified and excreted from the liver and circulates in 
the blood as a retinol binding protein (RBP)-retinol-transthyretin complex. 
Retinol is dissociated from RBP and delivered to cells.  The mechanism of 
retinol transport from plasma to cytoplasm is still unclear.  Intracellularly, retinol is 
bound to cellular retinol binding protein (CRBP).  There are three CRBPs; CRBP I, 
expressed in the liver, kidney and eye, CRBP II, mainly expressed in the small intestine, 
and CRBP III, expressed in the heart, muscle, adipose and mammary tissues [For a 
review please see:(34)].  Retinol is converted to either retinyl esters for storage by 
lethicin:retinol acyltransferase (LRAT) in the intestine or acyl-CoA-retinol acyltranserase 
(ARAT) in the liver, mammary gland, or adipose tissue or to retinaldehyde as an 
intermediate form before metabolism to ATRA by alcohol dehyrogenase (ADH) or 
retinol dehydrogenase (ROLDH).  Retinaldehyde is further metabolized to ATRA by 
retinal dehydrogenase (RALDH) (Fig. 1.2).   CRABP I catalyzes the degradation of 
ATRA to all-trans-4-oxo-retinoic acid to lower the active intracellular ATRA 
concentrations (35).  On the other hand, CRABP II transports ATRA to the nucleus 
where it interacts with retinoic acid receptors (RAR). 
The action of ATRA is mediated by nuclear RAR and retinoid X receptor (RXR), 
each consisting of three receptor types, α, β and γ.  The heterodimer of RAR and RXR 
with ligand regulates ATRA-mediated gene transcription by binding to retinoic acid 
response elements (RAREs) [for review see: (36)].  RAREs are cis-acting elements in 
the promoter regions of retinoid-responsive genes composed of direct repeats (DR) of the 
consensus half-site sequence AGGTCA separated by five nucleotides.  For example, 
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ATRA induces the expression of the RARβ through this mechanism regulating cell 
proliferation, growth and survival (37,38). 
 
3. COLON CANCER AND RETINOL 
As mentioned above, ATRA is thought to regulate most of the effects of retinoids, 
via the ATRA/RAR/RXR/RARE pathway.  Unfortunately, the period of inhibitory 
effect of ATRA on colon cancer is short due to acquisition of resistance to ATRA.  
ATRA resistance frequently occurs during cancer progression.  ATRA-resistance is due 
to a defect in RAR α, β, or γ induction in response to ATRA [for review see: (31,39-41)].  
The defective receptor varies with cell line but RARβ expression is frequently lost 
because of methylation of the RARE on the RARβ promoter region (39-42). 
Dietary retinyl-esters are converted to retinol in the intestinal lumen.  The 
intestinal lumen, including colonocytes, is primarily exposed to retinol.  Thus, dietary 
vitamin A supplementation can elevate retinol levels in the colon.  Once absorbed, 
retinol is esterified and transported to the liver, the major site of vitamin A storage.  
Although serum retinol levels in non-vitamin A deficient animals vary from 1-2 μM, 
regardless of supplementation status, [for a review please see: (43)], hepatic retinol levels 
increase in response to supplementation and values in excess of 90 μM have been 
reported (44).  Therefore, retinol could potentially be used to treat not only primary 
colon tumor growth but also liver metastases. 
Retinoids have been shown in numerous experimental situations to act as cancer 
chemopreventive and therapy agents [for review see: (30-32)].  Retinol, 9-cis-retinoic 
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acid (9-cis-RA), and 4-(hydroxyphenyl)retinamide (4-HPR) can inhibit the formation of 
carcinogen-induced aberrant crypt foci, a precursor to colon cancer, as well as colon 
tumors in rats (45-48).  Retinyl palmitate was recently shown to inhibit high fat diet-
induced aberrant crypt foci (45).  In addition, several in vitro studies illustrate that 
retinoids have potent antiproliferative effects on colon cancer cell lines and may hold 
potential for both chemoprevention and chemotherapy of colon cancer.  Taken together, 
it is more relevant to examine the effects of retinol on colon cancer cell growth and 
metastasis because (1) colonocytes are primarily exposed to retinol, (2) liver is the major 
storage site of retinol and colon cancer metastasis site, and (3) ATRA resistance is 
common in colon carcinomas.   
This dissertation focuses on the study of retinol as an inhibitor of ATRA-resistant 
human colon cancer cell line growth and metastasis in vitro and in vivo.  Chapter 1 
introduces background information concerning colorectal cancer progression and the role 
of retinol as a chemotherapy agent for colon cancer.  Chapter 2 will focus on the initial 
studies showing the mechanism of growth inhibition in ATRA-resistance colon cancer 
cells by retinol treatment independent of ATRA/RAR/RARE signaling.  Chapters 3 and 
4 are concerned with the ability of retinol to inhibit colon cancer cell invasion by 
decreasing MMP-2 and -9 activity as well as PI3K activity, respectively.  Chapter 5 will 
focus on the ability of dietary vitamin A supplementation to inhibit the liver metastasis of 
colon tumors in a nude mouse xenograft model.  Chapter 6 will summarize the findings 
of these studies and propose future directions to continue to understand the molecular 
mechanisms by which retinol inhibits the growth and metastasis of ATRA-resistant 







FIGURE 1.1.  GENETIC ALTERATIONS ASSOCIATED WITH COLON CARCINOGENESIS.  
Mutation in APC, K-ras, DCC and p53 transform normal colon epithelium to metastatic 





FIGURE 1.2.  A. RETINOID METABOLISM (34) AND B. SIGNALING VIA RAR, RXR 
AND RARE  
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Chapter 2: Retinol Inhibits the Growth of All-Trans-Retinoic Acid-




Retinol (vitamin A) is thought to exert its effects through the actions of its 
metabolite, all-trans-retinoic acid (ATRA), on gene transcription mediated by retinoic 
acid receptors (RAR) and retinoic acid response elements (RARE).  However, RA-
resistance limits the chemotherapeutic potential of ATRA.  We examined the ability of 
retinol to inhibit the growth of ATRA-sensitive (HCT-15) and ATRA-resistant (HCT-
116, SW620, and WiDr) human colon cancer cell lines.  Retinol inhibited cell growth in 
a dose-responsive manner.  Retinol was not metabolized to ATRA or any bioactive 
retinoid in two of the cell lines examined.  HCT-116 and WiDr cells did convert a small 
amount of retinol to ATRA, however this amount of ATRA was unable to inhibit cell 
growth.  To show that retinol was not inducing RARE-mediated transcription, each cell 
line was transfected with pRARE-CAT (chloramphenicol acetyltransferase) and treated 
with ATRA and retinol.  Although treatment with ATRA did increase CAT activity 
five-fold in ATRA-sensitive cells, retinol treatment did not increase CAT activity in any 
cell line examined.  To demonstrate that growth inhibition due to retinol treatment was 
independent of ATRA, RAR, and RARE, a pan RAR-antagonist was used to block RAR-
signaling.  Retinol-induced growth inhibition was not alleviated by the RAR-antagonist 
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in any cell line, but the antagonist did alleviate ATRA-induced growth inhibition of 
HCT-15 cells.  Retinol did not induce apoptosis, differentiation or necrosis, but did 
affect cell cycle progression.  Our data show that retinol acts through a novel, RAR-
independent mechanism to inhibit colon cancer cell growth. 
 
INTRODUCTION 
Colorectal cancer is currently the third leading cause of death due to cancer in the 
United States.  Retinoids, a group of compounds consisting of vitamin A (retinol), its 
natural metabolites, and several synthetic compounds, have been shown to act as cancer 
chemopreventive agents [for reviews see: (30-32)].  Retinol, 9-cis-retinoic acid (9-cis-
RA), and 4-(hydroxyphenyl)retinamide (4-HPR) can inhibit the formation of carcinogen-
induced aberrant crypt foci, a precursor to colon cancer, as well as colon tumors in rats 
(45-48).  Retinyl palmitate was recently shown to inhibit high fat diet-induced aberrant 
crypt foci (45).  In addition, several in vitro studies illustrate that retinoids have potent 
antiproliferative effects on colon cancer cell lines and may hold potential for both 
chemoprevention and chemotherapy of colon cancer.   
In almost all of the above studies, the retinoid examined has been an isoform of 
RA or a synthetic retinoid such as 4-HPR. Although these compounds are effective at 
inhibiting all-trans-RA (ATRA)-sensitive cell growth, the use of exogenous ATRA to 
study the effects vitamin A assumes that all of the biological phenomena attributed to 
retinol are due to ATRA.  The diet contains very little ATRA (33).  Rather, the diet 
contains vitamin A as: (1) previtamin A carotenoids and (2) preformed vitamin A as 
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retinol and retinyl esters.  Retinyl esters are cleaved within the intestinal lumen to yield 
retinol. Therefore, human colonocytes are exposed primarily to retinol, the focus of this 
study.  Within most cells, retinol is either esterified for storage or metabolized to 
ATRA.  ATRA effects cell growth and differentiation by binding to retinoic acid 
receptors (RARs), located in cell nuclei.  RARs heterodimerize with retinoid X 
receptors (RXRs) and bind to retinoic acid response elements (RAREs) located in the 
regulatory regions of retinoid-responsive genes.  When ATRA binds to the RAR 
member of the RAR/RXR heterodimer, gene transcription via RARE is induced [for 
review see: (31)].  
RA-resistance is believed to be due to a defect in RAR α, β, or γ induction in 
response to ATRA [for review see: (31,39-41)].  RA-resistance occurs when tumors or 
tumor-derived cell lines cease to growth inhibit or differentiate in response to treatment 
with ATRA.  Retinoic acid resistance is a common phenomenon and appears to arise 
spontaneously in numerous types of cancer and tumor-derived cell lines. The defective 
receptor varies with cell line but RARβ expression is frequently lost. 
The objective of the present study was to determine if retinol inhibits the growth 
of both ATRA-sensitive and ATRA-resistant colon cancer cell lines in vitro.  Because 
the ATRA-resistant cell lines lack one or more RARs, their use allowed us to determine 
the effects of retinol on cell growth, exclusive of the effects of ATRA.  Our data show 
that retinol itself inhibits the growth of both ATRA-sensitive and ATRA-resistant colon 
cancer cells through an ATRA and RAR independent mechanism. 
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MATERIALS AND METHODS 
Tissue Culture  
Three human colorectal adenoma cell lines, HCT-15, SW620, and WiDr, and one 
human colon carinoma cell line, HCT-116, were obtained from the American Type 
Culture Collection (Manassas, VA) and grown as recommended.  HCT-15 cells were 
grown in MEM, HCT-116 in McCoy’s medium, and SW620 and WiDr cells in DMEM in 
a humidified atmosphere at 37°C with 5% CO2.  All medium was supplemented with 
10% FCS (fetal calf serum) and antibiotics (1000 U/mL penicillin and 1000 μg/mL 
streptomycin).  The experiment was repeated with each cell line grown in either 
supplemented DMEM or McCoy’s medium.  Medium type did not affect cell growth.  
Cells were seeded in 12-well culture dishes at a density of 1 x 104 cells per well. The 
following day the medium was removed and replaced with medium containing 0, 0.1, 1 
or 10 μM ATRA or all-trans-retinol (Sigma, St Louis, MO).  All retinoids were 
prepared as 10 mM stocks in 100 % ethanol.  All treatments, including control, received 
equal volumes of ethanol vehicle and all retinoid manipulations were performed under 
subdued lighting.  All treatments were performed in duplicate.  Cells were harvested 
using trypsin and counted via hemocytometer every 24 h for four days.  
 
Retinoid Extraction and HPLC Analysis.  
To examine retinol metabolism, cells were seeded in 60 mm dishes at the 
following densities to yield 60 to 80% confluency and maximum HPLC detection 
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sensitivity at the time of harvest: 5 x 105 cells/dish for 24 h, 2.5 x 105 cells/dish for 48 h, 
1 x 105 cells/dish for 72 h, and 5 x 104 cells/dish for 96 h.  Twenty-four hours after 
plating, cells were treated with 0, 1, and 10 μM retinol for 24, 48, 72 or 96 h. Sixteen 
hours before harvest, the culture medium was removed and replaced with medium 
containing 5% FCS and 50 nmol/L [3H]retinol (specific activity = 52.5 Ci/mmol).  Cells 
and medium were harvested 2, 4, 8, and 16 h after the addition of label as described 
previously (50).  A control of labeling medium without cells was also incubated for 16 
h.  F9 murine teratocarcinoma cells, treated with 1 μM ATRA for 48 hr and incubated 
with 50 nM [3H]-retinol for 16 hr were used as a positive control for 4-oxoretinol 
production (17).  Retinoids were extracted and separated using a Waters Millennium 
HPLC system as described previously (51).  
 
Cell Transfection and CAT Assays.   
To examine the possibility that an undetected metabolite of retinol was activating 
RAR/RXR-mediated transcription, all cell lines were transiently transfected with 
pRARE-CAT (generously provided by Dr. Dianne Soprano, Temple University, 
Philadelphia, PA).  Cells were seeded on to 12-well plates at a density of 1.75 X 105 
cells/well, and incubated overnight in FCS-supplemented medium.  The following day 
cells were transfected using Lipofectamine 2000 (Promega, Madison, WI) according to 
the manufacturer’s protocol with 1 μg of pRARE-CAT and 0.5 μg of pSV-β-gal.  
Twenty-four hours later the transfection medium was removed and the cells were treated 
with fresh medium containing 0, 1, and 10 μM ATRA or retinol.  The cells were 
 17
harvested after treatment for 24 or 48 h and assayed for β-galactosidase (β-Galactosidase 
Enzyme Assay System, Promega, Madison, WI) and CAT (CAT Enzyme Assay System, 
Promega, Madison, WI) activity as per manufacturer’s instructions.  CAT activity was 
corrected for transfection efficiency using the β-galactosidase activity.   
 
RAR Antagonist Assays.   
To determine if retinol was inhibiting cell growth via RAR, the pan-RAR 
antagonist, AGN 193109 was used to block RAR function. The RAR pan-antagonist was 
synthesized by Allergan, Inc. (Irvine, CA).  Cell lines were plated at a density of 1 x 104 
in 12-well plates and allowed to attach overnight.  The following day, HCT-15 cells 
were treated with 0 and 1 μM ATRA or retinol with and without 10 μM AGN 193109.  
HCT-116, SW620, and WiDr cells were treated with 0 and 1 μM retinol with and without 
10 μM AGN 193109.  Control cells received an equal volume of DMSO and ethanol 
vehicle. Cells were harvested after treatment for 48 h (HCT-15) or 96 h (HCT-116, 
SW620, and WiDr).  All treatments were performed in duplicate.  The 
pharmacological, 10 μM, concentrations of ATRA and retinol were not examined 
because 100 μM AGN 193109 was toxic to the cells.   
 
Detection of Apoptosis.   
Nuclear staining via DAPI (4, 6-diamidino-2-phenylindole) and flow cytometry 
analysis, described below, were used to determine if cell growth inhibition was due to 
apoptosis.  For DAPI staining, cells were plated at 1 x 104 cells per well in 12-well 
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plates before treatment with 0, 1, and 10 μM retinol.  Cells incubated for 4 hr at 37ºC 
with 4 μg/mL camptothecin served as the positive control for apoptosis.  Both adherent 
and floating cells were harvested every 24 h for 4 d. The cells were centrifuged and 
washed with PBS to remove all traces of media.  Cells were then incubated with 2 
μg/mL DAPI for 10 min at 37ºC before counting at 400X magnification with an Olympus 
upright fluorescence microscope.  To obtain cell counts, at least three different locations 
on each slide were used. Two hundred cells were counted at each location yielding a 
minimum of 600 cells counted per slide.  Cells with segmented nuclei were scored as 
apoptotic. 
 
Cellular Differentiation.  
Alkaline phosphatase activity was used to determine if retinol was inhibiting cell 
growth by inducing cellular differentiation. All cell lines were plated on 60 mm dishes at 
a density of 5 x 104 cells per plate.  Twenty-four hours later, cells were treated with 0, 1 
and 10 μM retinol or 2 mM sodium butyrate (positive control) for 96 h.  Alkaline 
phosphatase activity was determined as described previously (52). Alkaline phosphatase 
activity was measured by the conversion of p-nitrophenyl phosphate (19.8 mM) to p-
nitrophenol by 0.1 mL of cell lysate in 100 mM glycine buffer, containing 1 mM MgCl2, 
pH 10. Alkaline phosphatase enzyme activity was corrected for lysate protein content and 
expressed as percent positive control. 
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Necrosis assays.   
Trypan blue exclusion assays were performed to measure cell death.  Briefly, an 
aliquot of the cells harvested for the growth curve assays was pelleted by centrifugation, 
resuspended in 0.5 mL HBSS, and incubated with an equal volume of 0.4% trypan blue 
solution (Sigma-Aldrich, St. Louis, MO) for five minutes at room temperature before 
counting with a hemocytometer.  Blue cells were scored as necrotic.  
 
Flow Cytometry Analysis.   
To determine if growth inhibition was due to cell cycle arrest and to confirm the 
absence of apoptosis through lack of a sub-G1 peak, cells were seeded on 60 mm dishes 
at a density of 3 x 105 (HCT15 and SW620) or 2 x 105 (HCT-116 and WiDr) cells per 
dish to provide 50-60% confluence at the time of harvest.  To synchronize, cells were 
plated in serum-free medium for 24 h and treated with 1 (HCT-15) or 3 μg/mL (HCT-
116, SW620, WiDr) aphidicholin for an additional 24 hr.  The following day, the cells 
were washed with PBS and treated with fresh FCS-supplemented media containing 0, 1, 
and 10 μM retinol.  Cells were harvested, fixed in 70% ethanol overnight and stained 
with 40 μg/mL propidium iodide as described previously (Ormerod).  At least 10,000 
cells were analyzed per sample using a FACSCalibur machine (Becton Dickinson, San 
Jose, CA).  DNA content was determined using Modfit software version 3.0 (Verity 




Growth of ATRA-resistant colon cancer cells is inhibited by retinol.   
The ability of retinol to inhibit cell growth was examined in three ATRA-resistant 
human colon cancer cell lines HCT-116 (42), SW620 (53), and WiDr (39).  HCT-15, an 
ATRA-sensitive cell line, was chosen to serve as a positive control for the inhibitory 
effects of ATRA on colon cancer cell growth (54). Serum concentrations of retinol range 
from 0.5 to 2 μM (55).  Therefore, 0.1 μM was selected to represent a sub-physiological, 
and 1 μM a physiological, concentration of retinol.  The highest level, 10 μM retinol, 
was used as a pharmacological, but potentially therapeutically relevant, concentration.  
There is very little ATRA (4-14 nM) in the serum (56,57).  ATRA levels were chosen to 
match the concentrations of retinol used and to reflect ATRA levels commonly found in 
the literature (39-41,58). 
After 96 h of treatment, the growth of HCT-15 cells was inhibited by ATRA 
(Figure 2.1A), as expected.  In addition, HCT-15 cell growth was also inhibited by 
retinol in a dose-responsive manner.  Cells treated with 10 μM retinol exhibited the 
largest degree of inhibition to 36.7 ± 7.8 % of control.  HCT-116 cell growth was 
inhibited slightly by 0.1 and 1 μM retinol and this decrease was not significant when 
compared to the same concentrations of ATRA (Figure 2.1B).  However, HCT-116 cell 
growth was significantly inhibited by 10 μM retinol (37.5 ± 9.2 % of control) when 
compared to 10 μM ATRA (74.3 ± 4.7 % of control).  SW620 and WiDr cell growth 
was significantly inhibited by treatment with 0.1 and 1 μM retinol for 96 h when 
compared to ATRA (Figure 2.1C and D) indicating that physiological levels of retinol 
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can inhibit the growth of ATRA-resistant cells.  At 10 μM concentrations, there was no 
significant difference in the ability of ATRA and retinol to inhibit SW620 and WiDr cell 
growth. The highest concentration of ATRA, 10 μM, inhibited cell growth slightly in all 
cell lines examined (Figure 2.1).  These data show that retinol can inhibit the growth of 
both ATRA-sensitive and ATRA-resistant colon cancer cells. 
 
Retinol is not metabolized to bioactive compounds.   
To determine if retinol was metabolized to a bioactive compound, such as ATRA, 
anhydroretinol (AR), or 4-oxoretinol, reverse-phase HPLC was performed on all cell 
lines as described previously (51).  To ensure that no transient bioactive retinoids were 
overlooked, retinol metabolism was examined after 24, 48, 72 and 96 h of treatment with 
0, 1, and 10 μM retinol followed by 2, 4, 8, and 16 h of incubation with 50 nM  [3H]-
retinol.  
HCT-15 and SW620 cells produced no [3H] -ATRA, 4-oxoretinol, or AR from 
[3H]-retinol at any time point or treatment (Figure 2.2).  The absence of [3H]-
4oxoretinol was also confirmed by northern blot analysis that failed to show CYP261A 
mRNA expression in any of the four cell lines examined (data not shown).  HCT-116 
and WiDr cells did synthesize a small amount of [3H]-ATRA from [3H]-retinol (Figure 
2.2).  However, both control and retinol-treated cells metabolized [3H]-retinol to [3H]-
ATRA.  The time point displayed in Figure 2.2 (48 h of retinol treatment followed 8 h 
of incubation with 50 nM [3H]-retinol) showed the largest concentration of 50 nM [3H]-
ATRA synthesis by HCT-116 and WiDr cells of any time point examined.  When 
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corrected for cell number, HCT-116 cells treated with the vehicle control synthesized 
0.15 nM [3H]-ATRA/million cells from 50 nM [3H]-retinol.  Cells treated with 10 μM 
retinol synthesized 0.55 nM [3H]-ATRA/million cells from 50 nM [3H]-retinol.  
Because the metabolism of 50 nM [3H]-retinol reflects the metabolism of 10 μM retinol 
(50,51,59), we can assume that if HCT-116 cells were treated with 10 μM retinol, 0.11 
μM of ATRA would be produced per million cells.  There were 5.4 x 106 cells on a 
duplicate plate of HCT-116 cells treated with 10 μM retinol for 96 h and included in the 
experiment shown in Figure 2.2.  As can be seen in Figure 2.1B, HCT-116 cell growth 
is inhibited only slightly by 0.1 or 1 μM ATRA when compared to control.  The amount 
or [3H]-ATRA synthesized from [3H]-retinol by WiDr cells was even less then that 
synthesized by the HCT-116 cell line.  Therefore, the small amount of ATRA produced 
by these cell lines when treated with 10 μM retinol cannot be responsible for the decrease 
in cell number that occurs when these cells are treated with 10 μM retinol. 
 
Retinol does not induce RARE-CAT reporter gene expression. 
Each colon cancer cell line was transiently transfected with pRARE-CAT and 
treated with ATRA or retinol to confirm that retinol was not metabolized to a bioactive 
compound that could transactivate RARE-mediated gene transcription.  The pRARE-
CAT construct contains only the nucleotides corresponding to the RARE found in the 
regulatory region of the RARβ2 gene linked to a CAT promoter. 
ATRA-sensitive HCT-15 cells show that treatment of with both 1 and 10 μM 
ATRA for 48 h resulted in an increase in CAT activity to 4.98 ± 0.39 -fold over control at 
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48 h (Figure 2.3A).  Because HCT-15 cells were ATRA-sensitive we were surprised to 
find that treatment of HCT-15 cells with retinol did not increase CAT activity to more 
then 1.80 ± 0.06 -fold over control at 48 h for cells treated with 1 μM retinol (Figure 
2.3A).  However, this lack of CAT activity reflects the metabolism data (Figure 2.2A-D) 
showing that HCT-15 cells do not metabolize retinol to ATRA.   
Neither ATRA nor retinol increased CAT activity more then 1.7-fold over control 
in any of the three ATRA-resistant colon cancer cell lines (Figure 2.3B-D).  The lack of 
CAT activity in cells treated with ATRA confirms the inability of these cells to respond 
to ATRA via RAR/RARE mediated mechanisms as described previously (39,42,53).  
Although the HCT-116 cells converted a small amount of [3H]retinol to [3H]ATRA, these 
cells lack RAR (42).  The absence of an increase in CAT activity in response to retinol 
treatment in the HCT-116 and WiDr cell lines shows that the small amount of ATRA 
produced by these cells does not induce RAR/RARE-mediated gene transcription. 
SW620 cells did not metabolize [3H]retinol to [3H]ATRA (Figure 2) and the lack of CAT 
activity in SW620 cells when treated with retinol both confirms the metabolism data and 
shows that an RAR-activating metabolite of retinol is either not present or is incapable of 
activating RAR/RARE-mediated gene transcription.  In summary, the inability of retinol 
to increase CAT activity in any of the cell lines examined, including ATRA-sensitive 
HCT-15 cells, demonstrates that retinol is not inducing RA-mediated gene transcription, 
confirming our metabolism data, and indicating that retinol may be acting exclusive of 
the RAR to inhibit colon cancer cell growth. 
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Retinol is not acting through the RAR to inhibit cell growth.   
To confirm that the growth inhibition exhibited by cells treated with retinol was 
not mediated by the RA/RAR/RARE retinoid signaling mechanism, all cell lines were 
treated with a RAR pan-antagonist, AGN 193109.  This antagonist, when added at 10-
times the concentration of agonist, blocks the ability of agonist to bind to RAR (60).  
HCT-15 cells treated with 1 μM ATRA and 10 μM AGN 193109 served as a positive 
control for the ability of AGN 193109 to block RAR-mediated cell growth inhibition. 
Because 1 μM ATRA does not inhibit HCT-116, SW620, or WiDr cell growth we did not 
test the effects of the combined treatment of AGN 193109 and ATRA in these cell lines.  
As shown in Figure 2.4A, AGN 193109 blocked ATRA-induced growth inhibition in 
HCT-15 cells, as expected.  However, AGN 193109 did not block growth inhibition due 
to retinol treatment in any of the four cell lines examined, including the ATRA-sensitive 
HCT-15 cell line (Figure 2.4). The inability of AGN 193109 to block retinol-induced 
growth inhibition confirms the results of the metabolism and RARE-reporter experiments 
which also indicate that retinol is not acting via RA/RAR/RARE to affect cell growth 
even in the ATRA-sensitive, HCT-15 cell line.  Unlike the ATRA-resistant cell lines, 
HCT-15 cells contain all of the cellular machinery required for induction of 
ATRA/RAR/RARE-mediated gene transcription and growth inhibition (39).  As shown 
in Figure 2.4A, ATRA is acting via this mechanism to inhibit the growth of HCT-15 
cells.  In contrast, retinol is acting via a novel, receptor-independent mechanism to 
inhibit the growth of both ATRA-resistant and surprisingly, ATRA-sensitive human 
colon cancer cell lines. 
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Retinol does not induce apoptosis, differentiation, or necrosis in ATRA-resistant colon 
cancer cells.   
To determine the mode by which retinol inhibits the growth of colon cancer cells, 
apoptosis was examined by nuclear staining using DAPI (Figure 2.5, left column) and 
FACS analysis of DNA content (Figure 2.6).  The percentage of DAPI-stained cells 
exhibiting segmented nuclei was less then 10% in all cell lines at all time points and 
treatments examined. FACS analysis failed to detect a sub-G1 peak in any of the cell lines 
when treated with retinol, confirming the absence of apoptosis (Figure 2.6).  
Additionaly, in all cell lines, less than 4% apoptosis was detected with TUNEL assay and 
no apoptosis was detected by PAR-P cleavage or DNA laddering (data not shown).  
Therefore, retinol does not inhibit colon cancer cell growth by inducing apoptosis. 
Alkaline phosphatase assays were performed to determine if retinol was inhibiting 
colon cancer cell growth by inducing cellular differentiation.  Retinol does not induce 
alkaline phosphatase activity in HCT-116, SW620, or WiDr cells (Figure 2.5, right 
column).  Retinol increased alkaline phosphatase activity slightly in HCT-15 cells 
(Figure 2.5A).  In contrast, treatment with sodium butyrate resulted in a large increase in 
alkaline phosphatase activity in each cell line.  These data indicate that retinol is not 
inhibiting cell growth by inducing cellular differentiation in the three ATRA-resistant cell 
lines.  A small increase in alkaline phosphatase activity in HCT-15 cells treated with 
retinol may indicate that cellular differentiation accounts for part of the retinol-induced 
decrease in growth. 
To ensure that retinol was not inducing necrosis, trypan blue dye exclusion assays 
were performed on the adherent cells used for the growth curve experiments described in 
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Figure 2.1.  The percent of cells that stained with trypan blue dye varied between 0.1 
and 7% and no consistent pattern was exhibited under any treatment condition at any time 
point (data not shown).  Therefore, necrosis is not responsible for the growth inhibition 
exhibited by colon cancer cells treated with retinol.  
 
 Retinol affects cell cycle progression. 
Treatment with 10 μM retinol increased the percentage of cells in G0/1 while 
decreasing the percentage of cells in S-phase in the HCT-15, SW620, and WiDr cell lines 
(Figure 2.6 A, C, and D).  Treatment with retinol decreased the percentage of HCT-15 
cells in G2/M, slightly increased the percentage of HCT-116 and SW620 cells in G2/M, and 
notably increased the percentage of WiDr cells in G2/M.  In contrast, the percentage of 
HCT-116 cells in G0/1 was not affected by retinol (Figure 2.6B), but retinol did decrease 
the percentage of HCT-116 cells in S-phase.  As can be seen in Figure 2.1D, control 
HCT-116 cells continued to divide in a linear manner, while HCT-116 cells treated with 
10 μM retinol ceased to divide between 24 and 48 h of treatment.  This result, when 
considered in light of the absence of apoptosis, differentiation, and necrosis in the HCT-
116 cell line despite strong growth inhibition by retinol, may indicate that retinol acts to 
slow the overall rate of cell division and increase the generation time of this cell line.  
 
DISCUSSION 
This study shows that retinol inhibits the growth of both ATRA-sensitive and 
ATRA-resistant human colon cancer cell lines.  We provide three lines of evidence that 
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retinol is acting independent of the established ATRA/RAR/RARE retinoid signaling 
pathway.  The first line of evidence indicates that retinol is not metabolized to bioactive 
compounds, such as ATRA, in two out of the four cell lines examined.  The remaining 
two cell lines synthesized only small amounts of ATRA from retinol.  Second, we show 
that retinol does not activate RARE-mediated gene transcription.  Finally, we present 
evidence that a RAR-antagonist blocks the ability of ATRA to inhibit the growth of 
ATRA-sensitive HCT-15 cells, as expected, but does not block the ability of retinol to 
inhibit the growth of any cell line examined.  The most surprising outcome of this study 
is that retinol is not acting through a RAR-dependent pathway in ATRA-sensitive HCT-
15 cells.  Therefore, even in the presence of functioning RAR, retinol does not inhibit 
cell growth by the actions of its metabolite ATRA, because this metabolite is not present 
in ATRA-sensitive HCT-15 cells (Figure 2.2). 
The ability of retinol to inhibit colon cancer cell growth is particularly interesting 
given that colon cancer cell lines produce little or no ATRA (Figure 2.2).  This finding 
is supported in a recent study by Jette et al (61) that used northern blot analysis to show 
that colon cancer cell lines, including HCT-116, lack retinol dehydrogenases, and 
therefore the ability to synthesize ATRA.  The metabolism of retinol by colon cancer 
cells was not examined in the study by Jette et al (61).  In contrast, our data shows that 
the HCT-116 cell line is capable of synthesizing very small amounts of ATRA from 
retinol (Figure 2.2).  This discrepancy is perhaps due to the ability of HPLC to detect 
extremely small amounts of 3[H]-retinoids, compared to the relative lack of sensitivity of 
northern blot analysis.   
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4-Oxoretinol and AR are two naturally occurring retinoids capable of inhibiting 
cell growth.  4-Oxoretinol acts via RARs (17), much like ATRA, whereas AR acts via a 
receptor-independent cytosolic mechanism to inhibit cell growth (62,63).  Neither 
compound was formed from retinol by any of the cell lines we examined (Figure 2.2).  
We cannot eliminate the possibility that an unknown bioactive metabolite of retinol was 
formed that existed only briefly or was not detected by our HPLC protocol.  However, 
the metabolism data is supported by the inability of retinol to induce CAT-activity in 
cells transfected with a pRARE-CAT construct (Figure 2.3) as well as the inability of a 
pan-RAR antagonist to block the effects of retinol on cell growth (Figure 2.4). 
We chose to use the pan-RAR antagonist, AGN 193109 to block RARs because 
this compound exhibits a high affinity for RAR (60).  Although a genetic approach 
would have been more specific, the dominant negative RAR construct available is 
activated by retinol (64), making it inappropriate for this study.  Therefore, we included 
a positive control, showing that AGN 193109 blocks ATRA-induced growth inhibition in 
the HCT-15, ATRA-sensitive cell line (Figure 2.3A), to indicate that AGN 193109 is 
functioning to block RAR-mediated growth inhibition. 
Retinoids have been previously shown to inhibit cancer cell growth by increasing 
cellular differentiation, inducing apoptosis, or causing cell cycle arrest.  With respect to 
colon cancer, retinoids tend to induce tumor apoptosis both in vitro (39,65,66) and in 
vivo(47,67).  The cell lines examined in this study showed no apoptosis in response to 
retinol treatment (Figure 2.5 left column, Figure 2.6).  In contrast, retinol induced G0/1 
arrest in three of the cell lines examined (Figure 2.6).  Although retinol failed to 
increase the percentage of cells in G0/1 in the HCT-116 cell line, growth inhibition in 
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these cells could be due to an overall increase in generation time because retinol does 
decrease cell growth (Figure 2.1B).  The differing responses between the HCT-116 cell 
line and the other three may reflect the heterogenicity of these cell lines, tumor stage 
(carcinoma versus adenoma), and presence or absence of various proteins in each cell 
line, for example APC (adenomatous polyposis coli) or p53.  
Retinoids tend to induce cell cycle arrest by blocking the G1 to S phase transition 
[for review see: (30)].  Unfortunately, the effect of retinoids on cell cycle regulatory 
proteins appears to be cell type specific (30).  For example, in carcinogen-exposed 
immortalized human bronchial epithelial cells, ATRA-induced G1 arrest is associated 
with decreased cyclin D1 protein levels due to ubiquitin-mediated degradation of cyclin 
D1 (68,69).  In contrast, ATRA-induced G1 arrest in MCF-7 breast cancer cells is 
associated with decreased pRB phosphorylation, while cyclin D1, p21WAF1/CIP1, cdk4 and 
cdk6 activity either does not change or decreases slightly, depending on the study (70-
72).  
This study shows that retinol is acting independent of the RAR to inhibit colon 
cancer cell growth.  Previously, retinoids have been shown to exert their receptor-
independent effects via interactions with protein kinase C alpha (PKCα) (73), F-actin 
(74), c-Raf kinase (62), regulating mitochondrial membrane potential (75), generating 
reactive oxygen species (76), increasing intracellular ceramide levels (77), activating c-
Jun N-terminal kinase (78), inducing ubiquitin-dependent proteolysis (68,69), and 
affecting MAP kinase (79,80), phosphatidylinositol 3-kinase (PI3K)/Akt (81), and 
epidermal growth factor receptor (EGFR) signaling (82).  The Hammerling lab has 
shown that the retroretinoids, retinol, and ATRA can bind PKCα and affect its redox 
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activation (73).  In contrast to our present study, they speculate that retinol antagonizes 
AR and increases cell survival by binding to c-Raf and augmenting its response to 
reactive oxygen species generated during UV irradiation, however the link between cell 
growth and c-Raf activation was not directly examined (62).   Because AR induces 
apoptosis we do not expect retinol to be affecting cell growth by interacting with c-Raf or 
any of the other pathways listed above that induce apoptosis.   
In conclusion, this study shows that retinol acts through a novel mechanism to 
inhibit the growth of both ATRA-sensitive and ATRA-resistant colon cancer cells by 
affecting cell cycle progression.  Resistance to ATRA is a common phenomenon and 
limits the use of RA-derivatives as chemotherapy.  We speculate that retinol, or a 
derivative of it, may prove an effective therapy to treat colorectal cancer. 
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FIGURE 2.1.  RETINOL INHIBITS THE GROWTH OF ATRA-RESISTANT HUMAN 
COLON CANCER CELLS 
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FIGURE 2.1.  RETINOL INHIBITS THE GROWTH OF ATRA-RESISTANT HUMAN 
COLON CANCER CELLS.  HCT-15 (A) HCT-116 (B), SW620 (C), and WiDr (D) cells 
were seeded and treated with 0, 0.1, 1 or 10 μM ATRA or retinol.  All treatments were 
performed in duplicate.  Cells were counted via hemocytometer daily for four days.  
Results represent the mean ± SE for three experiments. Panels in the left column display 
the percent growth inhibition exhibited by human colon cancer cell lines after 96 h of 
treatment with increasing amounts of ATRA or retinol. Statistical analysis was performed 
using t-tests comparing ATRA to retinol for each concentration.  *Indicates significantly 
different from ATRA, P < 0.05.  Panels in the right column show the growth rates of 
HCT-15 (A), HCT-116 (B), SW620 (C) and WiDr (D) cells grown for four days with 
increasing amounts of retinol. 
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FIGURE 2.2.  RETINOL IS NOT METABOLIZED TO BIOACTIVE COMPOUNDS IN HCT-
15 AND SW620 CELLS BUT IS CONVERTED TO ATRA BY HCT-116 AND WIDR CELLS. 
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FIGURE 2.2.  RETINOL IS NOT METABOLIZED TO BIOACTIVE COMPOUNDS IN HCT-
15 AND SW620 CELLS BUT IS CONVERTED TO ATRA BY HCT-116 AND WIDR CELLS.  
Cells were plated and allowed to attach for 24 hr before addition of medium containing 0, 
1, or 10 μM retinol. Cells were allowed to grow for 24, 48, 72 or 96 hr before the 
medium was removed and replaced with new medium containing 5% FCS and 50 nM 
[3H]-retinol.  The concentration of nonradioactive retinol in 5% FCS was ≈ 50 nM (51).  
Cells were allowed to incubate for another 2, 4, 8 or 16 hr before harvest.  The retinoids 
were extracted from cell and medium samples and separated by HPLC as described (51).  
Data shown represent radiolabeled retinoids extracted from medium (A) or cells (B) of 
the indicated cell lines 48 h after treatment with 0 or 10 μmol/L retinol followed by 
incubation for 8 h with 50 nM [3H]-retinol. The identities of the retinoids were 
determined by coelution with known nonradiolabeled (cold) standards included in the 
samples. Changes in absorbance are recorded as changes in voltage by the FloOne 
software that generated these chromatographs and controls the liquid scintillation 
counter.  Thus, the units for the y-axis of “Standards” panel are volts.  The slight 
difference in elution time between the cold standards and the [3H]-peaks is due to the 
transit time from the photo diode array to the scintillation counter. [3H]-Retinol extracted 
from labeling medium at time zero is shown in the left column, one panel from the 
bottom. F9 murine teratocarcimona cells were treated with 1 μmol/L RA for 48 hr 
followed by incubation with [3H]-retinol for 16 hr prior to retinoid extraction.  The 
retinoids extracted from F9 murine teratocarcimona cells are included as a positive 
control for 4-oxoretinol production and are shown in the last panel of the right column. 
Retinoid standards are shown in the bottom panel of the left column and eluted as 
follows: 4-oxoretinol, 13.5 min; ATRA, 18.5 min; all-trans retinol, 34.0 min, and AR, 
39.8 to 40.5 min.  This experiment was repeated twice with similar results.   
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FIGURE 2.3.  RETINOL DOES NOT INDUCE RARE-CAT REPORTER GENE 
EXPRESSION.  HCT-15 (A), HCT-116 (B), SW620 (C), and WiDr (D) cells were 
transiently transfected with 1 μg pRARE-CAT and 0.5 μg pSV-β-gal using lipofectamine 
2000.  Twenty-four hours following transfection, cells were treated with 0, 1, and 10 
μM RA or retinol.  Cells were harvested 24 and 48 h after treatment and CAT and β-
galactosidase assays were performed.  CAT activity was normalized for transfection 
efficiency using the β-galactosidase activity. The CAT activity in control cells treated 
with the ethanol vehicle was set equal to one and all other values are expressed as fold 
induction.  Values shown are the mean ± SE of three separate experiments. 
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FIGURE 2.4.  RETINOL DOES NOT ACT THROUGH RAR TO INHIBIT CELL GROWTH.  
HCT-15 (A) cells were plated with 0 or 1 μM RA or retinol with or without 10 μmol/L of 
the RAR pan-antagonist, AGN 193109, for 48 h.  HCT-116 (B), SW620 (C), and WiDr 
(D) were treated with 0 or 1 μM retinol with or without 10 μM AGN 193109 for 96 h.  
All treatments were plated in duplicate.  Data shown are the mean of two separate 
experiments ± SE. 
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FIGURE 2.5.  RETINOL DOES NOT INDUCE APOPTOSIS OR CELLULAR 
DIFFERENTIATION IN ATRA-RESISTANT HUMAN COLON CANCER CELL LINES. 
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FIGURE 2.5.  RETINOL DOES NOT INDUCE APOPTOSIS OR CELLULAR 
DIFFERENTIATION IN ATRA-RESISTANT HUMAN COLON CANCER CELL LINES.  
HCT-15 (A), HCT-116 (B), SW620 (C), and WiDr (D) cells were plated and treated with 
0, 1 or 10 μM retinol as described in Materials and Methods.  To measure apoptosis (left 
column), floating and adherent cells were harvested every 24 hr, centrifuged and washed 
with PBS to remove all traces of media.  Cells were stained with 2 μg/mL DAPI for 10 
min in 37ºC before observation.  To measure cellular differentiation (right column), cells 
were plated as described and treated with 0, 1, or 10 μM retinol or 2 mM sodium butyrate 
for 96 h.  Alkaline phosphatase activity was determined as described (Turowski) by the 
conversion of p-nitrophenyl phosphate to p-nitrophenol at 410 nm.  Alkaline 
phosphatase enzyme activity is expressed as percent positive control.  Data shown are 




FIGURE 2.6.  RETINOL ALTERS CELL CYCLE PROGRESSION BUT DOES NOT INDUCE 
APOPTOSIS. 
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FIGURE 2.6.  RETINOL ALTERS CELL CYCLE PROGRESSION BUT DOES NOT INDUCE 
APOPTOSIS.  HCT-15 (A), HCT-116 (B), SW620 (C), and WiDr (D) cells were 
synchronized with serum starvation for a total of 48 h and the addition of aphidicholin 
during the last 24 h of serum starvation.  Following synchronization, fresh medium 
containing 10 % FCS and 0 (left column) or 10 μM retinol (right column) was added for 
24 h, prior to fixation and staining with propidium iodide.  At least 10,000 cells were 
analyzed per sample using a FACS Calibur machine.  Absence of a sub-G0/1 indicates 
that apoptosis was not induced by retinol treatment.  Dark gray, G0/1 and G2/M; hatched, 
S-phase.  One representative experiment of two is shown.  
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Chapter 3: Retinol inhibits the invasion of retinoic acid-resistant colon 
cancer cells in vitro and decreases matrix metalloproteinase mRNA, 
protein, and activity levels 
ABSTRACT 
Retinol inhibits the growth of all-trans-retinoic acid (ATRA)-resistant human 
colon cancer cell lines through a retinoic acid receptor (RAR)-independent mechanism.  
The objectives of the current study were to determine if retinol inhibited the invasion of 
all-trans-retinoic acid (ATRA) -resistant colon cancer cells independent of RAR and the 
effects of retinol on matrixmetalloproteinases (MMP).  Retinol inhibited the migration 
and invasion of two ATRA-resistant colon cancer cell lines, HCT-116 and SW620, in a 
dose-dependent manner.  To determine if transcription, particularly RAR-mediated 
transcription, or translation of new genes was required for retinol to inhibit cell invasion, 
cells were treated with retinol and cycloheximide, actinomycin D, or a RAR pan-
antagonist.  Treatment of cells with retinol and cycloheximide, actinomycin D, or a 
RAR pan-antagonist did not block the ability of retinol to inhibit cell invasion. In 
addition, retinol decreased MMP-1 mRNA levels in both cell lines, MMP-2 mRNA levels 
in the SW620 and MMP-7 and -9 mRNA levels in the HCT-116 cell line.  Retinol also 
decreased the activity of MMP-2 and -9 and MMP-9 protein levels while increasing 
TIMP (tissue inhibitor of matrixmetalloproteinase)-1 media levels.  In conclusion, 
retinol reduces the metastatic potential of ATRA-resistant colon cancer cells via a novel 
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Colorectal cancer is the third most common cancer and cause of death due to 
cancer in the United States (1).  Death is generally not due to the primary, localized 
tumor, but to the metastasis of the cancer to other tissues, primarily the liver.  The 
escape of primary tumor cells into the circulation (intravasation) and the invasion of these 
tumor cells into the new target tissue (extravasation) to establish metastases requires 
digestion of and migration through the extracellular matrix (ECM).  The digestion of the 
ECM is performed by matrixmetalloproteinases (MMP), a large family of proteases [For 
a review please see: (8,9)].  MMP are classified by their substrates into different groups, 
collagenases, gelatinases, stromelysins, membrane-type MMP, matrilysins, and 
macrophage elastases, etc.  Increased serum or tissue levels and activity of MMP-1, -2, -
7, -9 and -13 are associated with colorectal cancer progression [(83,84); for a review 
please see: (9)].  MMP must be cleaved to be active and MMP activity is regulated both 
at cleavage and total protein levels.  MMP activity is also regulated by TIMPs (tissue 
inhibitor of matrixmetalloproteinase), which function as endogenous protease inhibitors 
[For a review please see: (9,85)].  TIMP-1 inhibits the activity of all MMP.  In 
addition, TIMP-1 binds to pro-MMP-9 to inhibit its conversion to active MMP-9. [For a 
review please see (9)]. 
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The retinoids, a group of compounds consisting of vitamin A (retinol), its natural 
metabolites, and several synthetic compounds, have been shown to inhibit metastasis in a 
variety of model systems.  For example, dietary retinyl palmitate supplementation 
decreases malignant melanoma metastasis in mice (86).  In addition, all-trans-retinoic 
acid (ATRA), an active metabolite of dietary vitamin A, decreases gastric cancer (87) and 
colon cancer cell invasion (88) in vivo.  Numerous studies have shown that ATRA 
reduces tumor cell invasion and metastasis in vitro by decreasing MMP mRNA, protein 
levels or enzyme activity as well as increasing TIMP mRNA or protein levels.  
However, to our knowledge, the ability of retinol, the form of vitamin A derived from the 
diet, to inhibit tumor cell invasion by altering MMP mRNA and protein levels or activity 
has not been explored. 
ATRA exerts its effects by binding to retinoic acid receptors (RARs).  The 
RARs function as heterodimers with retinoic X receptors (RXRs).  When ligand bound, 
the RAR/RXR heterodimer activates gene transcription via retinoic acid response 
elements (RAREs) located in the regulatory regions of retinoid-responsive genes [for a 
review please see (89)].  The clinical effectiveness of ATRA is limited by ATRA-
resistance, defined as the inability of ATRA to inhibit cell growth and induce 
differentiation. ATRA-resistance is a common phenomenon associated with cancer 
progression and is believed to be due to the inability of ATRA to induce RAR gene 
expression in ATRA-resistant cells (90-93).  
Because the diet contains almost no ATRA, the use of exogenous ATRA to study 
the effects of vitamin A assumes that all of the biological phenomena attributed to retinol 
are due to ATRA.  Preformed dietary vitamin A is consumed as retinyl esters that are 
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cleaved within the intestinal lumen to yield retinol.  The concentration of ATRA in the 
circulation is very low (1-14 nM) (94).  In contrast, serum retinol concentrations range 
from 0.5 to 2 μM (55).  Therefore, colonocytes are primarily exposed to retinol, the 
focus of the present study, via the diet and the circulation.  We have previously shown 
that retinol, but not ATRA, inhibits the growth of ATRA-resistant colon cancer cell lines 
through an ATRA and RAR-independent mechanism (95).  The use of ATRA-resistant 
cell lines allows us to examine the effects of retinol exclusive of those of ATRA.  For 
example, the ATRA resistant cell lines used in this study lack one or more of the RAR 
and either lack the ability to metabolize retinol to ATRA, as is the case for the SW620 
cell line, or produce only very small amounts of ATRA from retinol, as is the case for the 
HCT-116 cell line (95).  Importantly, treatment of these cells lines with ATRA or retinol 
does not induce the transcription of a RARE-chloramphenicol acetyltransferase (CAT) 
reporter construct in either cell line and the RAR pan-antagonist, AGN 193109, was 
unable to block the inhibitory effects of retinol on tumor cell growth (95).  Inhibition of 
primary tumor growth is only one aspect of a successful chemotherapeutic agent, 
therefore the objective of the present study was to examine the ability of retinol to inhibit 
ATRA-resistant colon cancer cell metastasis in vitro.  Because ATRA has been shown 
to inhibit cell invasion by decreasing MMP activity and increasing TIMP, we also 
explore the effect of retinol on MMP mRNA and protein levels, MMP enzyme activity, 
and TIMP protein concentration. 
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MATERIALS AND METHODS 
Tissue Culture   
The human carcinoma cell line, HCT-116, and the human colorectal adenoma cell 
line, SW620, were obtained from the American Type Culture Collection (Manassas, VA) 
and grown as recommended.  HCT-116 cells were grown in McCoy’s medium and 
SW620 cells in DMEM in a humidified atmosphere at 37°C with 5% CO2.  All medium 
was supplemented with 10% FBS (fetal bovine serum) and antibiotics (1000 U/mL 
penicillin and 1000 μg/mL streptomycin).  
 
Migration and Invasion Assays  
HCT-116 and SW620 cells were serum starved for 48 h before seeding at a 
density of 1 x 105 cells/well.  Uncoated Boyden chambers were used to assess the effect 
of retinol on cell migration while Matrigel coated Boyden chambers (Becton Dickinson, 
Franklin Lakes, NJ) were used to determine the ability of retinol to inhibit cell invasion 
through a basement membrane.  To measure cell migration, the upper portion of the 
chambers contained 0 (ethanol vehicle control), 0.1, 1, or 10 μM retinol. Retinol was 
prepared as 10 mM stock in 100 % ethanol.  All treatments, including control, received 
equal volumes of ethanol vehicle and all retinol manipulations were performed in the 
dark.  A filter containing pores 8 μm in diameter separated the cells from a lower 
chamber containing 10% FBS, which served as a chemoattractant.  After 8 h all cells 
were removed from the upper chamber using a cotton swab.  Cells that had migrated 
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through the membrane were fixed in methanol prior to staining with propidium iodide.  
The bottom of the filter was examined microscopically and the number of stained cells 
present in ten random fields of view were counted with a 20X objective on an Olympus 
upright fluorescence microscope to determine cell migration as described (96). 
To examine the effect of retinol on cell invasion, the upper portion of the 
chambers contained 0 (ethanol vehicle control), 1, or 10 μM retinol while the lower 
portion, separated by an 8 μm pore-sized filter coated with Matrigel, contained 20 ng/ml 
hepatic growth factor (HGF) (Sigma-Aldrich, St. Louis, MO) and 10% FBS, which 
served as chemoattractants.  Cell invasion was measured after 24 h.  All cells 
remaining in the upper portion of the chamber were removed.  Cells that had migrated 
through the membrane were fixed in methanol prior to staining with propidium iodide 
and quantified, as described above.   
To determine if the effects of retinol on cell invasion required the transcription, 
particularly RAR-mediated transcription, or translation of new genes, cells were treated 
with 2 mg/ml actinomycin D, 10 μg/ml cycloheximide, or 10 μM of a RAR pan-
antagonist (AGN193109, Allergan, Irvine, Ca), with or without 1 or 10 μM retinol added 
to the upper portion of Matrigel-coated Boyden chambers.  Twenty-four h later, cell 
invasion was quantitated as described above.  
To confirm the role of MMP-2 and –9 in colon cancer invasion, MMP activity 
was blocked using specific antibodies against MMP-2 (#AB809, Chemicon, Temecula, 
CA) and MMP–9 (#AB19016, Chemicon, Temecula, CA).  Control cells were incubated 
with a non-specific IgG antibody (#SC-2027, Santa Cruz Biotechnology, Santa Cruz, 
CA).  HCT-116 and SW620 cells were plated in Matrigel-coated Boyden chambers as 
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described above.  Antibody (10 μg/ml) was added to the upper portion of the chambers 
and 20 ng/ml of HGF was added to the lower portion of the chamber, containing medium 
supplemented with 10% FCS, to serve as a chemo-attractant.  After 24 h, cells that had 
moved through the membrane were visualized by propidium iodide staining and 
quantitated. 
 
RNA extraction and quantitative real time RT-PCR   
Cells were plated at a density of 1x 106 cells/100 mm dish. After 24 h, cells were 
treated with 0 (ethanol vehicle control), 1, or 10 μM retinol. Twenty-four h later total 
RNA was extracted with RNAstat (Tel-Test, Inc, Friendswood, Texas).  Reverse 
transcription was performed from 2 μg of total RNA using oligo-dT and AMV reverse 
transcriptase (Promega, Madison, WI) according to manufacture’s instructions.  The 
RNA was incubated for 10 min at 70°C and subsequently subjected to reverse 
transcription for 15 min at 42°C, followed by heating at 95°C for 5 min.  The sequences 
of the primers used are displayed in Table 1.  The identity of the amplified PCR product 
was confirmed by sequence analysis.  Quantitative real time-reverse transcriptase (RT)-
PCR was performed with SYBR Green dye (Perkin-Elmer-Applied Biosystems, Foster 
City, CA) using an ABI 7900HT (Perkin-Elmer-Applied Biosystems, Foster City, CA) 
according to the manufacturer’s instructions.  Briefly, an initial denaturation step (10 
min at 95°C) was followed by a two-step PCR (15 s at 95°C; 1 min at 60°C, 40 cycles).  
PCR reactions were performed in duplicate.  Relative amounts of MMP cDNA were 
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calculated by the comparative CT method (97).  CT values obtained for the different 
MMP were normalized to corresponding CT values of GAPDH.  
 
Zymography   
HCT-116 and SW620 cells were plated at a density of 2 x 106 cells/100 mm dish.  
Cells were washed with PBS twice and treated with 0 (ethanol vehicle control), 1, or 10 
μM retinol in serum free media for 24 h.  MMP-2 activity was detected in serum-free 
media concentrated using a centricon column with a 10 kDa cutoff value (Millipore, 
Volketswil, Switzerland).  MMP-9 activity was measured in serum-free media incubated 
with MMP-9 antibody at a 1:500 dilution and 20 μl of protein A/G plus agarose bead/mL 
(#SC-2003, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C.  The 
following day the beads were washed with 1% NP-40 three times and then once with 
PBS.   Sample buffer (0.1 M Tris⋅HCl (pH 8.6), 10% Glycerol, 0.0025% bromophenol 
blue) was used to elute MMP-9 from the agarose beads prior to zymography. 
Zymograms were prepared as described previously (98).  Equal amounts of 
protein were separated using a 0.1% gelatin/10% SDS-PAGE gel.  After electrophoresis, 
the gels were washed in 2.5% Triton X-100 for 1 h at room temperature and incubated 
overnight with developing buffer (Invitrogen, Carlsbad, CA) at 37°C.  Gels were stained 




Western blot analysis 
To determine TIMP-1 and MMP-9 protein levels, HCT-116 and SW620 cells 
were plated and treated with retinol as described above for zymography.  Following 
treatment, the serum-free media was concentrated 10-fold using centricon columns with a 
10 kDa cutoff value (Millipore, Volketswil, Switzerland).  The concentrated media were 
electrophoresed through 8% SDS-PAGE gels for MMP-9 and 12 % SDS-PAGE gels for 
TIMP-1 and transferred to nitrocellulose membranes.  To examine the level of 
intracellular TIMP-1, HCT-116 and SW620 cells were lysed in RIPA buffer (150 mM 
NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS, 50 mM Tris, 1 mg/ml leupeptin, 1 mM 
DTT, 2 mM NaOV4, 1 mg/ml PMSF, 1 mg/ml trypsin inhibitor, and 10 mM aprotinin) 24 
h after treatment with retinol.  Cell lysate protein concentrations were determined using 
the BioRad DC protein assay kit (Hercules, CA).  Protein (50 μg) was electrophoresed 
through a 12% SDS-PAGE gel and transferred to a nitrocellulose membrane.  
Membranes were blocked with 5% milk in TBST (10 mM Tris, pH 8, 150 mM NaCl, and 
0.5% Tween-20) for 1 h at room temperature before MMP-9, TIMP-1, and β-actin 
antibodies (Sigma-Aldrich, #A2066, St. Louis, MO) were added at a 1:2000 dilution. 
MMP-9 (#AB19016), and TIMP-1 (#AB800-50) antibodies were purchased from 
Chemicon (Temecula, CA).  After incubation with the corresponding secondary 
antibody at a dilution of 1:2000, immunoreactivity was detected using the Pierce 
Horseradish Peroxidase Super Signal West Pico Chemiluminescent Substrate kit 




Values shown are the mean ± SEM of at least three independent experiments 
unless otherwise indicated.  All statistical tests were performed using SPSS (Apache 
Software Foundation, Wilmington, DE, version 12.0 for Windows).  Data were analyzed 
using two-tailed t-tests comparing each retinol concentration to control (0 μM) with the 
exception of the data shown in Fig. 2 and 5.  In the case of Fig. 2, two-tailed t-tests were 
used to compare samples with and without cycloheximide, actinomycin D, and AGN 
193109.  In Fig. 5, two-tailed t-tests were used to compare cell invasion between each 
specific MMP antibody and control cells treated with a non-specific IgG antibody.  
Results were considered significantly different at P < 0.05. 
 
RESULTS 
Retinol inhibits cell migration and cell invasion in vitro   
The ability of retinol to inhibit the migration of ATRA-resistant colon cancer cells 
was examined in two ATRA-resistant human colon cancer cell lines: HCT-116 (90) and 
SW620 (99).  Serum concentrations of retinol range from 0.5 to 2 μM (55).  Therefore, 
0.1 μM was selected to represent a sub-physiological, and 1 μM a physiological, 
concentration of retinol.  The highest level, 10 μM retinol, was used as a 
pharmacological, but potentially therapeutically relevant, concentration.  In HCT-116 
cells, 0.1, 1, and 10 μM retinol decreased cell migration to 50.0 ± 17.1%, 35.4 ± 15.2%, 
and 27.9 ± 17.1% of vehicle control, respectively (Fig. 3.1A). Treatment with 0.1, 1, and 
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10 μM retinol reduced SW620 cell migration to 58.7 ± 11.6%, 36.5 ± 8.9%, and 36.4 ± 
7.2% of vehicle control, respectively (Fig. 3.1A).  Treatment with retinol for 8 h did not 
decrease cell number (data not shown).  
Because cell migration is only one facet of metastatic potential, we determined 
whether retinol could inhibit the ability of colon cancer cells to digest and move through 
Matrigel, a basement membrane-like protein matrix, in vitro.  The ability of HCT-116 
cells to invade through Matrigel was decreased to 52.6 ± 15.9% and 40.0 ± 6.7% of 
vehicle control by 1 and 10 μM retinol, respectively (Fig. 3.1B).  SW620 cell invasion 
was decreased by 1 and 10 μM retinol to 81.2 ± 19.0% and 46.0 ± 15.0% of vehicle 
control, respectively (Fig. 3.1B).  Cell number was not affected after 24 h of treatment 
with retinol (data not shown).  These data show that retinol inhibits both cell motility 
and invasion through an ECM.  
 
The effect of retinol on cell invasion is RAR-independent  
To elucidate whether retinol mediated cell invasion through increased gene 
transcription or mRNA translation, HCT-116 and SW620 cells were treated with 
cycloheximide or actinomycin D.  HCT-116 cells treated with 1 μM retinol and 
actinomycin D were significantly less invasive than cells treated with 1 μM retinol alone, 
indicating that transcription may be required for invasion in this cell line (Fig. 3.2B). 
Importantly, treatment with cycloheximide (Fig. 3.2A) or actinomycin D (Fig. 3.2B) did 
not block the inhibitory effect of retinol on cell invasion in either cell line, suggesting that 
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increased gene transcription and translation do not mediate the inhibitory effect of retinol 
in cell invasion. 
In most ATRA-sensitive cells, the actions of retinol are mediated by its 
metabolite, ATRA, which acts by binding to RARs and inducing gene expression via 
RAREs.  However, HCT-116 cells lack all RAR (90) and, while SW620 cells may 
express some RARs (93,99), we have shown that retinol inhibits HCT-116 and SW620 
colon cancer cell growth independent of ATRA and the RARs (95).  To determine if the 
inhibitory effect of retinol on cell invasion was also RAR-independent and to confirm our 
actinomycin D data, we used the RAR pan-antagonist, AGN193109, to block RAR 
signaling and ensure that any RARs present would be inactive.  This antagonist, when 
added at 10 times the concentration of agonist, blocks the ability of agonist to bind to 
RAR (100).  Cells were treated with 0 or 1 μM retinol with and without 10 μM AGN 
193109.  The 10 μM concentration of retinol was not examined in this experiment 
because 100 μM AGN193109 was toxic to the cells.  As can be seen in Fig. 3.2C, the 
RAR-antagonist did not alleviate the inhibitory effect of retinol on cell invasion.  These 
data show that retinol inhibits the invasion of colon cancer cells independent of RAR and 
new protein or mRNA synthesis.   
 
Retinol decreases MMP mRNA levels 
MMP facilitate the cell invasion by digesting the ECM.  To determine whether 
the retinol-induced decrease in cell invasion was due solely to lower cell motility or also 
to a decrease in ECM digestion, we examined the mRNA levels of five MMP using 
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quantitative real-time RT-PCR.  The gelatinases MMP-2 and MMP-9, matrilysin MMP-
7, and the collagenases MMP-1 and MMP-13 are believed to be important in colorectal 
cancer metastasis (8).  Treatment with 10 μM retinol reduced MMP-2 mRNA levels to 
63 ± 8% of control in SW620 cells but not in HCT-116 cells (Fig. 3.3A). In contrast, 
MMP-9 mRNA levels were reduced to 69 ± 4% of control by treatment with 10 μM 
retinol in HCT-116 cells (Fig. 3.3B).  Treatment with 1 μM retinol reduced MMP-9 
levels to 57 ± 1.5 % of control in the SW620 cell line but treatment with 10 μM retinol 
did not lower MMP-9 mRNA levels, indicating that different concentrations of retinol 
may exert varying effects on MMP-9 mRNA levels in this cell line.  The mRNA level of 
MMP-7 was decreased in HCT-116 cells to 60 ± 11% of vehicle control by 10 μM retinol 
treatment, but MMP-7 mRNA was not affected by retinol treatment in SW620 cells (Fig. 
3.3C).  Treatment with 10 μM retinol decreased MMP-1 mRNA levels to 48 ± 8% and 
44 ± 8% of vehicle control in HCT-116 and SW620 cells, respectively (Figure 3.3D).  In 
contrast, retinol treatment of HCT-116 and SW620 cells did not change mRNA levels of 
MMP-13 (Fig. 3.3E).  These data suggest that retinol may decrease cell invasion by 
reducing MMP mRNA levels in vitro. 
 
Retinol decreases gelatinase (MMP-2 and -9) enzyme activity 
We further investigated whether retinol decreased the enzyme activity and protein 
levels of the MMP whose transcription it altered.  Retinol treatment decreased MMP-9 
enzyme activity and total levels of active MMP-9 in the conditioned media obtained from 
both the HCT-116 and SW620 cell lines (Fig. 3.4).  No pro-MMP-9 was detected in the 
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conditioned media (Fig. 3.4B and D).  Retinol treatment also decreased MMP-2 activity 
in conditioned media from SW620 cells (Fig. 3.4C) but did not affect pro-MMP-2 levels 
in this cell line.  Although MMP-2 mRNA was decreased by retinol treatment in HCT-
116 cells (Fig. 3.3), neither pro- nor active-MMP-2 levels were decreased by treatment 
with retinol in conditioned media from HCT-116 cells (Fig. 3.4A).  Although retinol 
decreased the mRNA levels of MMP-1 and -7 and these enzymes are important for cell 
invasion, we were unable to detect MMP-1 and -7 enzyme activity or protein using the 
MMP-1 Biotrak Activity Assay System (GE Healthcare Bio-Sciences Corp., Piscataway, 
NJ), which detects both active and total MMP-1, or casein zymogel and western blotting 
of conditioned media, to detect MMP-7, in both cell lines (data not shown) potentially 
because these cell lines secrete low levels of MMP-1 and -7 (101,102).  These data 
suggest that retinol may reduce the invasion of colon cancer cell lines in vitro by 
reducing the protein levels and activity of the gelatinases, MMP-2 and, particularly, 
MMP –9.  
 
MMP –2 and –9 are involved in colon cancer cell invasion 
Next, we verified that the MMP whose protein or activity levels were decreased 
by retinol treatment played a role in the invasion of these cell lines through Matrigel.  
Specific, neutralizing antibodies were used to block the activity of MMP-2 and -9 in in 
vitro invasion assays.  Cell invasion was decreased to 19 ± 12% by an MMP-9 
neutralizing antibody in the HCT-116 cell line (Fig. 3.5A).  However, in the HCT-116 
cell line, the MMP-2 neutralizing antibody only decreased cell invasion to 59 ± 10% of 
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that exhibited by control cells, indicating that MMP-2 may play a smaller role in the 
invasion of this cell line through Matrigel than MMP-9.  This data reflects that shown in 
Fig. 3.4A where MMP-2 activity was not decreased, but MMP-9 activity was decreased, 
by retinol treatment in HCT-116 cells.  In the SW620 cell line, invasion was decreased 
to 26 ± 7% and 29 ± 27% by MMP-2 -and -9 neutralizing antibodies, respectively (Fig. 
3.5B), suggesting that MMP-2 and –9 are involved in SW620 colon cancer cell invasion 
through Matrigel.  Similarly, both MMP-2 and –9 activity were decreased by retinol 
treatment in SW620 cells (Fig. 3.4B). 
 
Retinol increases TIMP-1 protein levels in conditioned media 
Because MMP-9 activity is regulated by TIMP-1, western blot analysis of cell 
lysates and conditioned medium as well as quantitative real-time RT-PCR were used to 
examine the effect of retinol on TIMP-1 protein and mRNA levels.  Retinol treatment 
increased TIMP-1 protein levels in media but not in cell lysates (Fig. 3.6A and B).  
Unlike other TIMPs, TIMP-1 is inducible. TIMP-1 protein concentration is controlled at 
the level of transcription, mRNA stability, protein degradation, and endocytosis (85).  
Retinol slightly decreased TIMP-1 mRNA levels to 86 ± 5% and 85 ± 4% of control in 
HCT-116 cells treated with 1 and 10 μM retinol, respectively, but not in SW620 cells 
(Fig. 3.6C-D).  Importantly, retinol does not increase TIMP-1 mRNA or protein levels 
in the cell lysates (Fig. 3.6C-D) and the inhibitory effect of retinol on cell invasion is not 
blocked by actinomycin D or cycloheximide treatment (Fig. 3.2).  Therefore, if TIMP-1 
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is mediating the inhibitory effect of retinol on cell invasion, retinol may be increasing 
extracellular TIMP-1 levels by decreasing TIMP-1 degradation or endocytosis. 
 
DISCUSSION 
This study demonstrates that retinol decreases the invasion of human colon cancer 
cell lines in vitro (Fig. 3.1).  The inhibitory effects of retinol are not dependent upon 
increased gene transcription via RAR or mRNA translation (Fig. 3.2).  Depending on 
cell line, retinol treatment also decreased the mRNA levels of MMP-1, 2, -7 and -9 (Fig. 
3.3) as well as the activity of MMP-2 and -9 and total media MMP-9 protein levels (Fig. 
3.4).  The specific MMP affected varied with cell line but the ability of retinol to 
decrease MMP-9 protein and activity levels was consistent between both cell lines.  
TIMP-1 binds to pro-MMP-9, inhibiting the activation of pro-MMP-9 (9).  TIMP-1 
levels were also increased by retinol treatment in the media collected from both cell lines 
(Fig. 3.6).  Taken together, these data suggest that retinol, the form of vitamin A derived 
from the diet, inhibits the invasion of colon cancer cell lines in vitro by decreasing their 
ability to digest ECM proteins.   
It is important to note that the colon cancer cell lines used in the present study 
produce little (HCT-116) or no (SW620) ATRA (95).  Other groups have also found 
that colon cancer cell lines lack the ability to synthesize ATRA from retinol (103).  In 
addition, the colon cancer cell lines used in the present study do not convert retinol to 4-
oxoretinol or anhydroretinol, two naturally occurring retinoids capable of inhibiting cell 
growth (95).  Therefore, we hypothesize that retinol itself, and not a bioactive 
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metabolite, inhibits colon cancer cell invasion.  It is possible that an unknown and 
undetected bioactive metabolite of retinol was formed that existed only briefly and was 
not identified in our previous study, however we have also previously shown that retinol 
cannot induce CAT-activity in cells transfected with a pRARE-CAT construct (95).  In 
the present study, the inability of a pan-RAR antagonist to block the inhibitory effects of 
retinol on cell invasion (Fig. 3.2) supports our conclusion that retinol inhibits cell 
invasion by an ATRA and RAR-independent mechanism. 
Although the cell lines used in the present study either do not express RAR or 
express only some RAR (90,93,99) we used the RAR pan-antagonist, AGN 193109, to 
block any potential RAR activation in the current study and ensure that the effects of 
retinol on cell invasion would be exclusive of ATRA and RAR.  AGN 193109 exhibits a 
high affinity for all RAR (100) and we have shown previously that AGN 193109 blocks 
the inhibitory effects of ATRA on ATRA-sensitive cell growth (95).  Although a genetic 
approach would have been more specific, the dominant negative RAR construct available 
is activated by retinol (104), making it inappropriate for this study.   
The ability of MMPs to digest the ECM is regulated at the mRNA, protein, and, 
most importantly, enzyme activity level.  The current study is the first, to our 
knowledge, to show that retinol inhibits colon cancer cell invasion in vitro by decreasing 
MMP-1, -2 and –9 mRNA, MMP-9 protein, and MMP-2 and –9 activity exclusive of 
ATRA and RAR.  In vitro, ATRA reduces breast cancer cell invasion by decreasing 
MMP-9 activity (105).  ATRA has also been shown to decrease MMP-1 and -9 activity 
in diabetic human skin organ culture (106) and MMP-7 protein excretion and active 
MMP-7 levels in the human colon cancer cell line, BM314 (88).  ATRA has been 
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shown to decrease MMP-1 mRNA levels in MDA-MB-231 cells (107) and decrease 
MMP-1 and –2 mRNA and protein levels while increasing TIMP-1 and 2 protein levels 
in cultured melanoma cells (108).  Treatment of rat invasive prostate adenocarcinoma 
cells with ATRA decreased cell invasion by inhibiting MMP-2 and -9 activity (109).  
Finally, ATRA has also been shown to decrease MMP-9 and increase TIMP-1 gene 
expression in murine lung alveolar carcinoma (110).  These studies indicate that ATRA 
can alter MMP mRNA, protein and enzyme activity levels as well as increase TIMP-1 
concentrations in a variety of cell systems.  In the studies mentioned above, the MMP 
affected by ATRA varied with cell type, reflecting our data.  Interestingly, MMP-2 and-
9 appear to be the most frequently regulated by ATRA. 
Serum and tissue levels of the gelatinases MMP-2 and –9 are correlated with 
colon cancer stage and prognosis in animal and clinical studies [For a review please see: 
(9)]. Collins et al (10) and Ornstein and Cohn (11) showed that MMP-2 mRNA was 
significantly increased in Duke’s stage B and C tumors.  Koumura et al (111) found that 
a higher incidence of MMP-9 expression in colorectal tumors occurred when liver 
metastases were present.  MMP-2 protein levels also increase as polyps progress to 
adenocarcinoma (112) and are increased in Duke’s D stage (13,14).  In addition, MMP-
2 protein is found at the invasive edge of colon tumors (113).  MMP-2 activation has 
also been shown to be increased in patients with metastases (15).  Elevated active 
MMP-2 was found in the bile of patients with liver metastases when compared to patients 
with colon cancer but without liver metastases (114).  Like MMP-2, increased MMP-9 
protein and activity levels are also associated with Duke’s staging (13).  MMP-9 is more 
frequently expressed in the invasive regions of advanced tumors (115).  Serum MMP-9 
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levels, although of inactive MMP, are also elevated in patients with liver metastases 
(114).   
As mentioned previously, TIMPs inhibit MMP activation.  Although TIMP-1 is 
capable of affecting the activity of many MMP, TIMP-1 specifically binds to pro-MMP-
9, inhibiting its activation [For a review please see: (9)].  Our data show that retinol 
treatment increases TIMP-1 protein levels in the medium of both cell lines (Fig. 3.6).  
The increase in media TIMP-1 levels (Fig. 3.6A and B) occurs concomitant with 
decreased MMP–9 activity in both cell lines (Fig. 3.4).  It is possible that TIMP-1 may 
bind to and prevent the activation of any pro-MMP-9 present in the culture media, 
thereby inhibiting cell invasion, however no pro-MMP-9 was detected in the tissue 
culture media (Fig. 3.4).  Therefore, the lower MMP-9 activity most likely reflects the 
decrease in MMP-9 mRNA and protein levels, and not the increase in media TIMP-1 
protein, that occurs in response to retinol treatment (Fig. 3.3 and 3.5).  
In contrast to what might be expected based on in vitro studies (116-118), 
elevated serum TIMP-1 levels are correlated with a poor disease outcome in clinical 
studies (119-122).  In such cases, TIMP’s tumor promoting activities were not linked to 
its ability to inhibit MMP (123-126).  Rather, the poor clinical outcome of patients with 
elevated TIMP-1 levels is thought to be due to the stimulatory activity of TIMP-1 on cell 
growth.  However, in our study, retinol did not affect cell growth after 24 h of treatment 
(data not shown), the time at which media levels of TIMP-1 were measured.  The link 
between serum TIMP-1 levels, MMP activity, and clinical outcome requires further 
study.  Because our study used Matrigel-coated Boyden chambers, it lacked the full 
complement of ECM proteins that occur in vivo, therefore future studies will be 
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conducted utilizing an animal model to assess the effect of retinol on MMP and TIMP-1 
levels on colon cancer metastasis.  
In conclusion, the present study shows that retinol inhibits colon cell invasion by 
decreasing MMP activity and increasing TIMP-1 levels in vitro through an ATRA and 
RAR-independent mechanism.  While the particular MMP affected varied with cell line, 
MMP-9 mRNA and protein levels were decreased in both ATRA-resistant cell lines 
examined.  Retinol also increased TIMP-1 levels in conditioned media obtained from 
both cell lines.  The ability of retinol to decrease the metastatic potential of ATRA-
resistant colon cancer cell lines suggests that dietary vitamin A supplementation may 
prevent colon cancer progression. 
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Table 3.1.  Sequence of primers used for SYBG quantitative real time-PCR 
 
 
Target Gene Sense primer (5’-3’) Antisense primer (5’-3’) 
MMP-1 GATGAAGTCCGGTTTTTCAAAG GCAGCATCGATATGCTTCAC 
MMP-2 CGGAAAAGATTGATGCGGTA TGCTGGCTGAGTAGATCCAG 
MMP-7 (127) GGATGGTAGCAGTCTAGGGATTAACT GGAATGTCCCATACCCAAAGAA 
MMP-9 ATCCGGCACCTCTATGGTC CTGAGGGGTGGACAGTGG 
MMP-13 CCAGTCTCCGAGGAGAAACA AAAAACAGCTCCGCATCAAC 
TIMP-1 (128) CTTCTGGCATCCTGTTGTTG AGAAGGCCGTCTGTGGGT 
GAPDH 
(129) TGCACCACCAACTGCTAGC GGCATGGACTGTGGTCATGAG 
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FIGURE 3.1.  EFFECT OF RETINOL ON ATRA-RESISTANT COLON CANCER CELL 
MIGRATION AND INVASION.  HCT-116 (left column) and SW620 (right column) cells 
were serum starved for 48 h before seeding at a density of 1 x 105 cells/well.  Uncoated 
Boyden chambers were used to assess the effect of retinol on cell migration (A).  The 
upper portion of the chambers contained 0 (ethanol vehicle control), 0.1, 1, or 10 μM 
retinol.  An 8 μm pore-sized filter separated the cells from a lower chamber containing 
10% FBS, which served as a chemoattractant.  Cell migration was measured after 8 h by 
propidium iodide staining. All data are reported as mean ± SEM for three (HCT-116) or 
five (SW620) experiments.  Matrigel-coated Boyden chambers were used to examine 
the effect of retinol on cell invasion (B). The upper portion of the chambers contained 0 
(ethanol vehicle control), 1, or 10 μM retinol and the lower portion contained 20 ng/ml 
HGF and 10% FBS, which served as chemoattractants.  Cell invasion was measured 
after 24 h by propidium iodide staining as described in Materials and Methods.  All data 
are reported as mean ± SEM for n=3.  *Significantly different from control, P < 0.05. 
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FIGURE 3.2.  EFFECT OF CO-TREATMENT WITH RETINOL AND CYCLOHEXIMIDE, 
ACTINOMYCIN D OR A PAN-RAR ANTAGONIST ON ATRA-RESISTANT COLON 
CANCER CELL INVASION.  HCT-116 (left column) and SW620 (right column) cells 
were serum starved for 48 h before seeding at a density of 1 x 105 cells/well on Matrigel-
coated Boyden chambers. The upper portion of the chambers contained 0 (ethanol vehicle 
control), 0.1, 1, or 10 μM retinol with or without 10 μg/ml cycloheximide (CHX) (A) or 
2 μg/ml actinomycin D (Act D) (B).  Cells were also treated with 1 μM retinol with and 
without 10 μM AGN193109 (C).  The lower chamber contained 20 ng/ml hepatic 
growth factor and 10% FBS.  Cell invasion was measured after 24 h by propidium 
iodide staining as described in Materials and Methods.  All data are reported as mean ± 








FIGURE 3.3.  EFFECT OF RETINOL ON MMP MRNA LEVELS.  HCT-116 (right 
column) and SW620 (left column) cells were treated with 0 (ethanol vehicle control), 1, 
or 10 μM retinol for 24 h.  Five different MMP mRNA levels (A: MMP-2, B: MMP-9, 
C: MMP-7, D: MMP-1 and E: MMP-13) were detected by quantitative real time RT-
PCR. Quantitative real time RT-PCR reactions were performed in duplicate.  Data are 
reported as mean ± SEM, n=3.  Relative amounts of MMP cDNA were calculated by the 
comparative CT method.  CT values obtained for the different MMP were normalized to 





FIGURE 3.4.  EFFECT OF RETINOL ON MMP ACTIVITY AND PROTEIN LEVELS.  
HCT-116 (left columns, A and B) and SW620 (right column, C and D) cells were treated 
with 0 (ethanol vehicle control), 1, or 10 μM retinol for 24 h.  Gelatin zymograms (A 
and C) displaying the active form of MMP-9 (88-92 kDa) and both the pro and active 
forms of MMP-2 (72 kDa and 62 kDa, respectively) are shown. Western blots (B and D) 
displaying active (88-92 kDa) MMP-9 protein levels in serum free conditioned media 
harvested from cells treated for 24 h with retinol.  Pro-MMP-9 (95-98 kDa) was not 
detected in the conditioned media.  Each experiment was repeated three times and one 
representative experiment is shown. 
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FIGURE 3.5.  MMP ANTIBODIES BLOCK THE INVASION OF HCT-116 AND SW620 
CELLS.  HCT-116 (A) and SW620 (B) cells were serum starved for 48 h before seeding 
at a density of 1 x 105 cells/well on Matrigel-coated Boyden chambers.  The upper 
portion of the chambers contained 10 μg/ml of MMP-2 or -9 antibody in serum free 
media.  The lower chamber contained 20 ng/ml HGF and 10% FBS.  Cell invasion was 
measured after 24 h by propidium iodide staining as described in Materials and Methods.  





FIGURE 3.6.  EFFECT OF RETINOL ON TIMP-1 PROTEIN AND MRNA.  HCT-116 and 
SW620 cells were treated with 0 (ethanol vehicle control), 1, or 10 μM retinol for 24 h.  
Proteins were collected from HCT-116 (A) and SW620 (B) cells and culture media as 
described in Materials and Methods.  TIMP-1 protein was detected in cell lysates and 
conditioned media.  β-Actin is shown as a loading control for the cell lysates.  TIMP-1 
mRNA levels in HCT-116 (C) and SW620 (D) cells were detected by quantitative real 
time RT-PCR. Quantitative real time RT-PCR reactions were performed in duplicate.  
Data are reported as mean ± SEM, n=3.  Relative amounts of TIMP-1 cDNA were 
calculated using the comparative CT method.  CT values obtained for TIMP-1 were 
normalized to corresponding CT values of GAPDH.  *Significantly different from 
control, P < 0.05. 
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Chapter 4:  Retinol Decreases Phosphatidylinositol 3-Kinase Activity 
in Colon Cancer Cells 
ABSTRACT 
Previously, we showed that retinol inhibited all-trans-retinoic acid (ATRA)-
resistant human colon cancer cell invasion via a retinoic acid receptor-independent 
mechanism.  Because phosphatidylinositol 3-kinase (PI3K) regulates cell invasion, the 
objective of the current study was to determine if retinol affected PI3K activity.  
Following 24 h of serum starvation, the all-trans-retinoic acid resistant human colon 
cancer cell lines HCT-116 and SW620 were treated with 0, 1, or 10 μM retinol.  Thirty 
min of retinol treatment resulted in a significant decrease in PI3K activity in both cell 
lines.  To determine the mechanism by which retinol reduces PI3K activity, the levels 
and heterodimerization of the regulatory subunit, p85, and the catalytic subunit, p110, of 
PI3K were examined.  Retinol treatment did not alter p85 or p110 protein levels or the 
heterodimerization of these subunits at any time point examined.  To determine if retinol 
affected the ability of PI3K to phosphorylate the substrate, phosphatidylinositol (PI), 
PI3K was immunoprecipitated from control cells and incubated with 10 μg PI and 
increasing concentrations of retinol or 10 μg retinol and increasing concentrations of PI.  
Retinol decreased PI3K activity in a dose-responsive manner and increased PI suppressed 
the inhibitory effect of retinol on PI3K activity.  Finally, the PI3K inhibitor, LY294002, 
mimicked the ability of retinol to decrease cell invasion.  Computational modeling 
revealed that retinol may inhibit PI3K activity in a manner similar to that of wortmannin.  
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Thus, a decrease in PI3K activity due to retinol treatment may confer the ability of retinol 
to inhibit ATRA-resistant colon cancer cell invasion.   
 
INTRODUCTION 
Colorectal cancer is the third most common cancer and cause of death due to 
cancer in the United States.  The five-year survival rate for colorectal cancer patients 
with metastasis is only 10% (130).  Death due to colorectal cancer is generally caused 
by hepatic metastasis of the primary tumor, rather than the primary tumor itself (7).  The 
retinoids, a group of compounds consisting of vitamin A (retinol), its natural metabolites, 
and several synthetic compounds, have been shown to inhibit metastasis in a variety of 
model systems.  For example, dietary retinyl palmitate decreased malignant melanoma 
metastasis in mice (131).  All-trans-retinoic acid (ATRA) decreased breast cancer (132), 
gastric cancer (133), and colon cancer invasion (134) in vitro and rhabdomyosarcoma 
metastasis in rats (135).  Also, retinol decreased hepatic metastasis in a hamster model 
of pancreatic ductal carcinoma (136).  
Dietary retinyl-esters are converted to retinol in the intestinal lumen.  Thus, 
dietary vitamin A supplementation can elevate retinol levels in the colon.  Once 
absorbed, retinol is re-esterified and transported to the liver, the major site of vitamin A 
storage.  Although serum retinol levels in non-vitamin A deficient animals vary from 1-
2 μM, regardless of supplementation status, [for a review please see: (43)], hepatic retinol 
levels increase in response to supplementation and values in excess of 90 μM have been 
reported (44).  
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Phosphatidylinositol 3-kinases (PI3Ks) catalyze the phosphorylation of the 3-OH 
position of the inositol head groups of the phosphatidylinositol (PI) lipids, 
phosphatidylinos--itol(4)phosphate [PI(4)P], and phosphatidylinositol(4,5)bisphosphate 
[PI(4,5)P2] to generate PI(3)P, PI(3,4)P2 and PI(3,4,5)P3, respectively (16).  PI3Ks can 
be divided by three different main classes based on their lipid substrate and structure.  
Class IA PI3K consists of the regulatory subunit, p85, and the catalytic subunit, p110, 
and catalyzes the phosphorylation of all three substrates, PI, PI(4)P, and PI(4,5)P2.   
Activation of PI3K is associated with increased cell invasion and tumor 
metastasis (137,138).  In addition, PI3K activity is increased in human colon cancer 
(139).  PI3K activity is regulated by altering the protein levels or heterodimerization of 
the p85 regulatory and p110 catalytic subunits of PI3K.  ATRA has been shown to 
affect PI3K activity by increasing p110β mRNA (140) and protein levels or p85α mRNA 
and phosphorylation (141).  In addition, cellular retinol binding protein I (CRBPI) 
inhibits PI3K/Akt signaling by decreasing the heterodimerization of p85 and p110 
subunits of PI3K (142).  
ATRA inhibited airway smooth muscle cell migration by inhibiting PI3K/Akt-
dependent actin cytoskeleton reorganization (143).  Previously, we showed that retinol 
decreased the invasion of ATRA-resistant human colon cancer cells via a novel RAR-
independent mechanism (144).  The objectives of present study were to determine if 
retinol affected PI3K activity in ATRA-resistant human colon cancer cells and if 
inhibition of PI3K decreased the invasion of these cells. 
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MATERIALS AND METHODS 
Tissue Culture 
The human colorectal carcinoma cell line, HCT-116, and the human colorectal 
adenoma cell line, SW620, were obtained from the American Type Culture Collection 
(Manassas, VA) and grown in DMEM in a humidified atmosphere at 37°C with 5% CO2.  
Media were supplemented with 10% FBS (fetal bovine serum) and antibiotics (1000 
U/mL penicillin and 1000 μg/mL streptomycin).  All cells were serum starved for 24 h 
before retinol treatment.  Retinol was added to DMEM medium containing 10% FBS 
and antibiotics.  Retinol was dissolved in ethanol and all retinoid manipulations were 
performed under subdued light. 
 
PI3K Activity Assay 
HCT-116 and SW620 cells were plated at a density of 1 x 106 cells/100 mm dish 
and 2 x 106 cells/100 mm dish, respectively.  Cells were treated with 0, 1, and 10 μM 
retinol for 30 min following 24 h of serum starvation.  Cells were lysed with cell lysis 
buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium 
orthovanadate, 1 μg/ml Leupeptin and 1 mM PMSF).  Cell protein lysate concentrations 
were determined using the BioRad DC protein assay kit (Hercules, CA).  Total PI3K 
protein was detected using p85 antibody as described in the Western Blot Analysis 
section, below.  Total PI3K protein was normalized to β-actin.  PI3K proteins were 
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immunoprecipitated by incubation of 400 μg of whole cell protein lysate with 4 μg of 
IRS-1 antibody (Upstate, #06-248, Lake Placid, NY) overnight at 4°C.  The next day, 50 
μl of protein A/G plus-agarose beads (Santa Cruz Biotechnology, #sc-2003, Santa Cruz, 
CA) were added to the lysate and incubated for 2 h at 4°C.   
PI3K activity was determined as described previously (145) with minor 
modification as follows.  The beads were washed twice with 1% NP-40 and once with 
each of the following: PBS, LT (lithium Tris) buffer [0.5 M LiCl and 200 mM Tris-HCl 
(pH 7.5)], TEN (Tris, EDTA, sodium chloride) buffer (20 mM Tris-HCl (pH 7.5), 1 mM 
EDTA, and 100 mM NaCl), and TGN (Tris, EGTA, sodium chloride) buffer (20 mM 
Tris-HCl (pH 7.5), 1 mM EGTA, and 100 mM NaCl).  The washed beads were 
resuspended in 40 μl TGN buffer.  Immunoprecipitated PI3K was incubated with 10 μg 
phosphatidylinositol PI (Avanti Polar Lipid, Alabaster, AL) for 10 min at room 
temperature followed by incubation with 10 μCi of [γ-32P] ATP and 20 mM MgCl2 for 20 
min at room temperature.  The reaction was stopped with 100 μl 1N HCl.  The samples 
were centrifuged for 1 min at 15,000 x g.  Following centrifugation, the supernatant was 
extracted with a 1:1 solution of chloroform:methanol and the lower fraction spotted on 
TLC (thin layer chromatography) plates (Fisher Scientific Company, Houston TX).  
Before use, the TLC plate was treated with coating solution (40% methanol, 1.2 mM 
EDTA and 1% potassium oxalate) for 30 min and dried overnight.  TLC separation 
buffer consisted of chloroform:methanol:30% ammonium hydroxide:H20 = 
129:114:15:21.  Dried TLC plates were exposed to film at –70°C for 3 to 5 d. 
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Western Blot Analysis 
Cells were plated at a density of 1 x 106 cells/100 mm dish.  Cells were treated 
with 0, 1, and 10 μM retinol for 30, 60, 120 and 240 min after 24 h of serum starvation.  
Western blot analysis was performed as described previously (146).  Protein (50 μg) 
was electrophoresed through 8% SDS-PAGE gels and transferred to nitrocellulose 
membranes.  Membranes were incubated with a 1:100 dilution of p110 antibody (Santa 
Cruz Biotechnology, #sc-8010, Santa Cruz, CA) in 5% BSA in TBST (Tris-buffered 
saline, Tween) overnight at 4°C or with a 1:100 dilution of p85 antibody (Santa Cruz 
Biotechnology, #sc-423, Santa Cruz, CA) in TBST overnight at 4°C.  
 
Immunoprecipitation of PI3K 
Cells were plated as described above in the PI3K Activity Assay section.  Cells 
were treated with 0 and 10 μM retinol for 5, 10, 20, 30, 60, and 120 min after 24 h of 
serum starvation.  Cells were lysed with cell lysis buffer as described in the PI3K 
Activity Assay section, above.  PI3K protein was immunoprecipitated by incubation of 
200 μg of whole cell protein lysate with 2 μg of p110 antibody overnight at 4°C.  The 
following day, 25 μl of sepharose 4A beads (50 mg/ml) (Amersham Biosciences, 
Piscataway, NJ) were added to the lysate prior to incubation for 2 h at 4°C.  The beads 
were washed twice with 1% NP-40 and once with PBS.  Protein samples were subjected 
to western blot analysis as described above.  
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PI3K Substrate Competition Assay 
Cells were plated as described above in the PI3K Activity Assay section.  Cells 
were treated with 10% FBS for 30 min following 24 h of serum starvation.  Cells were 
not treated with retinol prior to lysis.  Cells were lysed with cell lysis buffer as described 
in the PI3K Activity Assay section, above.  PI3K proteins were immunoprecipitated by 
incubation of 400 μg of whole cell protein lysate with 2 μg of p110 antibody overnight at 
4°C.  Following incubation, 25 μl of sepharose 4A beads (50 mg/ml) were added for 2 h 
at 4°C.   The beads were washed twice with 1% NP-40 and once with each of the 
following; PBS, LT, TEN, and TGN.  The washed beads were resuspended in 50 μl 
TGN buffer.  Ten μl samples were subjected to western blot analysis for p110 levels to 
serve as an internal loading control, as described above.  Immunoprecipitated PI3K was 
incubated with 10 μg PI, retinol vehicle (ethanol) or increasing concentrations of retinol 
(0, 10, 20, 50, and 100 μg; corresponding to 0, 0.6, 1.2, 2.9, and 5.8 μM retinol, 
respectively) for 10 min at room temperature prior to the addition of 10 μCi of [γ-32P] 
ATP and 20 mM MgCl2 for 20 min at room temperature.  In addition, 
immunoprecipitated PI3K was incubated with 10 μg retinol and increasing concentrations 
of PI (10, 20, and 50 μg).  The total volume of ethanol vehicle was the same in all 
samples, regardless of retinol concentration.  Lipid extraction and TLC were performed 




Cells were serum starved for 24 h before seeding at a density of 1 x 105 cells/well 
onto Boyden chambers coated with Matrigel.  The upper portion of the chambers 
contained 0 (ethanol vehicle control) or 10 μM retinol and 0, 10 or 50 μM of the PI3K 
inhibitor, LY294002.  DMEM containing 10% FBS was added to the lower portion of 
each chamber to serve as a chemoattractant.  After 24 h, all cells were removed from the 
upper chamber using a cotton swab.  HCT-116 cells that had migrated through the 
membrane were stained with crystal violet.  SW620 cells that had migrated through the 
membrane were fixed in methanol prior to staining with propidium iodide.  The bottom 
of the membrane was examined microscopically and the number of stained cells present 
in ten random fields of view counted to determine cell invasion as described (96). 
 
Computational Methods 
The Hyperchem 7.5 modeling environment was used to perform a series of 
calculations on retinol, wortmannin and a fragment of PI.  To decrease the 
computational complexity the native PI structure was fragmented by decreasing both of 
the ester chains to a single methyl group.  This model compound should remain 
representative of the larger structure as the activity of PI at PI3K is focused near the 
cyclohexyl and phosphate groups and not at the non-polar side chains, which instead 
interact with the cell membrane (147).  Structure pre-optimization was conducted using 
semi-empirical quantum mechanics with a MNDO/d parameterization.  Resulting 
structures were then carried forward to a more complex ab initio optimization using a 
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RHF/6-31G(d) model chemistry to generate not only a starting geometry for further 
calculations but more importantly a set of atomic charges for each of the atoms.   
Molecular dynamics was employed to interrogate the conformational space of the 
ligands via a series of simulated annealing experiments.  Since the compounds were all 
relatively small organics, all dynamics calculations were performed using an MM+ force 
field with electrostatic contributions to the potential energy term calculated using the 
atomic charges generated from the ab initio optimization.  The annealing cycle was 
conducted using a time step of 0.0005 ps and composed of a 5 ps heating step where the 
structure was taken from 0°K to 800°K, followed by a 30 ps production phase at constant 
temperature, before a final 10 ps cooling phase from 800°K back to 0°K.  This final 
cooled structure was then energy optimized and saved before becoming the starting 
structure for a subsequent annealing cycle.  The procedure was repeated 100 times to 
generate 100 candidate conformations for retinol, wortmannin and the PI fragment.  The 
100 conformations were sorted based on distances, angles and torsion angles of various 
moieties to produce a set of conformational families for each compound.  An 
electrostatic potential isosurface was generated for the lowest energy structure of each of 
these conformation families.  The isosurface provided a means of assessing the 
electrostatic character of each compound and facilitates comparisons of their potential 
substrate interactions by highlighting locations of high reactivity.  The ligands in this 
study were not docked to the p110 protein, but instead compared to each other to examine 




Quantitation was performed with Biorad Quantity One software.  Values shown 
are the mean ± SEM of three independent experiments.  All data are expressed relative 
to vehicle control.  All statistical tests were performed using SPSS (Apache Software 
Foundation, Wilmington, DE, version 12.0 for Windows).  Data were analyzed using 
two-tailed t-tests comparing each retinol concentration to control (0 μM).  Results were 
considered significantly different at P < 0.05. 
 
RESULTS 
Retinol decreases PI3K activity.   
Previously, we showed that retinol inhibited the invasion of HCT-116 and SW620 
ATRA-resistant human colon cancer cell lines (144).  Because PI3K plays a regulatory 
role in tumor metastasis (137,138), we examined the effect of retinol on PI3K activity in 
intact cells, treated with 0, 1 and 10 μM retinol for 30 min immediately prior to harvest.  
Retinol decreased PI3K activity in both the HCT-116 and SW620 cell lines (Fig. 4.1A 
and B).  Specifically, in the HCT-116 cell line, 1 and 10 μM retinol significantly 
decreased the activity of PI3K to 59.8 ± 11.4 and 70.3 ± 7.7% of vehicle control, 
respectively (Fig. 4.1A).  Treatment with 1 μM retinol trended to reduce PI3K activity 
in the SW620 cell line to 70.8 ± 11.4% of vehicle control (Fig. 4.1B).  Treatment with 
10 μM retinol also significantly reduced PI3K activity in the SW620 cell line to 71.6 ± 
5.9% of vehicle control (Fig. 4.1B).  There were no differences in PI3K activity between 
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the 1 and 10 μM retinol treatments in either cell line, indicating that maximal PI3K 
inhibition may have been achieved following treatment with 1 μM retinol.  These data 
indicate that treatment of intact ATRA-resistant colon cancer cells with retinol rapidly 
decreases PI3K activity.   
 
Retinol does not decrease p110 and p85 protein levels or heterodimerization.   
Western blot analysis and immunoprecipitation were used to determine if retinol 
decreased PI3K activity by reducing PI3K protein levels or if retinol affected the 
heterodimerization of the p85 and p110 subunits of PI3K.  As shown Fig. 1, PI3K 
activity was decreased after as little as 30 min of retinol treatment.  In addition, we 
showed previously that the ability of retinol to inhibit cell invasion was independent of 
transcription and translation (144).  Cells were treated with retinol from 30 to 240 min 
to determine the effect of retinol on p110 and p85 protein levels.  Retinol treatment did 
not alter either p110 or p85 protein levels at any time point examined (Fig. 4.2 A, B, D 
and E).   
Heterodimerization of p85 and p110 activates PI3K (16).  To determine retinol’s 
effect on the interaction of p85 and p110, cells were treated with retinol for 5 to 120 min.  
p110 antibody was used for immunoprecipitation and p85 antibody was selected for 
immunoblotting to detect the binding of p110 to p85.  Retinol treatment did not change 
p85 and p110 heterodimerization at any time point examined (Fig. 4.2 C and F).  These 
data indicate that retinol does not exert its inhibitory effect on PI3K activity by 
decreasing p85 or p110 protein levels or their heterodimerization.   
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Retinol decreases PI3K activity by inhibiting PI/PI3K interaction.   
To elucidate whether retinol decreased PI3K activity by inhibiting the ability of 
the PI3K substrate, PI, to interact with PI3K, we immunoprecipitated PI3K from non-
retinol-treated cell lysates and measured the activity of this purified PI3K in the presence 
of increasing amounts of retinol.  As can be seen in Fig. 4.3, the activity of PI3K was 
decreased by retinol in dose-dependent manner.  The activity of PI3K in HCT-116 and 
SW620 cells was significantly decreased to 21.3 ± 10.9 and 41.8 ± 19.7% of vehicle 
control, when incubated with 10 μg retinol (0.6 μM retinol) and 10 μg PI, respectively.  
In addition, the activity of PI3K was further reduced to 10.3 ± 4.3, 6 ± 3.6, and 6.4 ± 
3.4% of vehicle control by incubation with 20, 50, and 100 μg retinol, respectively 
(corresponding to 1.2, 2.9, and 5.8 μM retinol), in the HCT-116 cell line.  Similarly, in 
SW620 cells, the activity of PI3K was decreased to 14.6 ± 6.6, 11.6 ± 8.8, and 11.5 ± 
9.1% of vehicle control by incubation with 20, 50, and 100 μg retinol, respectively 
(corresponding to 1.2, 2.9, and 5.8 μM retinol). Retinol inhibits PI3K activity to a greater 
extent when PI3K is purified (Fig. 4.3) than when whole cells are treated with retinol 
(Fig. 4.1).  Thus, it is conceivable that the metabolism of retinol or the sequestration of 
retinol by binding proteins, such as CRBP-I, may modulate the ability of retinol to inhibit 
PI3K activity in intact cells. Importantly, the ability of retinol to more significantly 
inhibit the activity of immunoprecipitated PI3K demonstrates that retinol is directly 
affecting the enzyme-substrate interaction. 
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To determine if the ability of retinol to decrease PI3K activity was suppressed by 
PI, immunoprecipitated PI3K from non-retinol-treated HCT-116 cell lysates was 
incubated with 10 μg retinol and increasing concentrations of PI.  As can be seen in Fig. 
4.3C, the decrease in PI3K activity in response to retinol was suppressed by incubation 
with 50 μg of PI.  Specifically, 10 μg retinol (0.6 μM retinol) decreased PI3K activity to 
38.9 ± 15.9 % of vehicle control.  However, when treated with 10 μg retinol and 50 μg 
PI, PI3K activity increased to 110.0 ± 20.8 % of vehicle control.  These data suggest 
that retinol inhibits the interaction of PI3K with its substrate PI. 
 
Retinol and a PI3K inhibitor both decrease cell invasion.   
The PI3K inhibitor, LY294002, was used to determine if PI3K played a role in the 
invasion of the HCT-116 and SW620 cell lines.  As can be seen in Fig. 4.4, HCT-116 
and SW620 cell invasion was decreased following treatment with retinol and LY294002.  
Cell invasion was significantly decreased to 36 ± 6.2% by 10 μM retinol and to 37 ± 13.3 
and 28 ± 10.3% by 10 and 50 μM LY294002, respectively, in the HCT-116 cell line (Fig. 
4.4A).  In the SW620 cell line, invasion was significantly decreased to 31.6 ± 5.8% by 
10 μM retinol and to 20.5 ± 3.4 and 9.7 ± 0.8% by 10 and 50 μM LY294002, respectively 
(Fig. 4.4B).  Previously, we showed that cell number was not affected after 24 h of 
treatment with retinol (144).  These data indicate that PI3K is involved in the invasion 
of these ATRA-resistant colon cancer cell lines.  These results, together with those in 
Fig. 4.3, suggest that retinol may decrease cell invasion by inhibiting the activity of PI3K. 
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Retinol and wortmannin exhibit similar electrostatic potential surfaces. 
Extensive molecular modeling in the form of both ab initio calculations and 
molecular dynamics stimulations were performed to provide a better understanding of the 
reactivity of retinol, PI and wortmannin.  As expected the ab initio calculations revealed 
a number of non-zero atomic charges that were indicative of various degrees of polarity 
within the ligands.  The most polar of the three ligands was the PI fragment as there 
were a number of acidic hydrogens on the alcohol groups of the cyclohexyl ring as well 
as a significant charge gradient near the phosphate moiety.  Wortmannin also contained 
a number of electron dense areas, but fewer acidic hydrogens overall as the most reactive 
hydrogen was the one attached directly to the five-membered furan ring.  These results 
parallel those reported by x-ray crystallography that suggested this particular hydrogen 
atom was directly involved with PI3K complexation (148).  Retinol was observed to 
contain only one acidic hydrogen atom, the one located on the alcohol group, and thus 
based on polarity alone might be considered the least reactive ligand as a majority of the 
molecule is encompassed by a relatively non-polar hydrocarbon ring and hydrocarbon 
chain. 
The simulated annealing procedure generated conformational families for retinol 
that could be categorized by the distance between the terminal alcohol group and the ring, 
the angle the ring formed with the midpoint of the carbon chain and the hydroxyl group, 
and the torsion angles along the unsaturated hydrocarbon chain.  The vast majority of 
the structures formed one major family that showed folding of the hydrocarbon chain 
inward toward the ring as the pi orbitals of the unsaturated carbon-carbon double bonds 
aligned to form a ring-like structure.  The elongated conformation that left the hydroxyl 
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group completely extended away from the ring was also identified, albeit with less 
frequency.  Although it lacked orbital stabilization, this elongated conformation was 
relatively low in energy because of the low steric interactions caused by the extension of 
the hydrocarbon chain. 
The PI fragment results were categorized by the torsion angles near the phosphate 
moiety and the relative spatial distance between the two ester linkages and the hydroxyl 
laden ring.  While the interaction of the ester functionalities with the ring is favorable in 
the model compound, structures that adopted this form were eliminated from 
consideration because the active form of PI has the two lengthy carbon chains extended 
away from the binding site, and located in the cell membrane (147), not folded over the 
ring.  The presence of these folded conformations was simply an artifact of the adoption 
of the model fragment.  Instead, only the PI structures that maintained their extended 
nature were considered for the subsequent calculations.  Not surprisingly only one major 
conformational family was identified for wortmannin as a majority of the compound’s 
structure is built around a relatively rigid ring scaffold. 
Electrostatic potential surfaces for the most prominent conformations of the 
compounds are presented in Fig. 4.5.  Here, areas of positive potential are depicted by 
the green wire frame whereas negative potentials are shown in purple.  For reference the 
potential is displayed over the tube structure of the compound with carbon atoms in blue, 
oxygen atoms in red, hydrogen atoms in white and phosphorus shown in yellow.  The 
first surface in Fig. 4.5A shows the reactive hydrogen atom of wortmannin (white arrow) 
located between two relatively negative potential areas created by the lone pairs of 
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electrons on the oxygen atoms of the furan and neighboring ring (red arrows).  The 
distance across the positively charged pocket is calculated to be approximately 3.5Å. 
A typical surface for the PI fragment is shown in Fig. 4.5C.  In this case, the 
numerous reactive hydroxyl atoms lie nestled between a number of negative zones 
created by the various hydroxyl oxygen atoms and a large negative charge created by the 
doubly bonded oxygen atom of the phosphate.  Measuring across the gap from the 
potential minimum located near the phosphate to the nearest neighboring negative zone 
places a relatively acidic hydrogen atom in a pocket of about 5.4 Å.  Thus, wortmannin 
and PI appear to exhibit some similarity in their electrostatic surface in that there are 
alternating positive and negative zones that surround relatively reactive hydrogen atoms.  
However, the electron distribution is very different between the two as wortmannin has 
only one reactive hydrogen atom that is inserted between two large electron dense areas 
creating only one pocket of high reactivity whereas the PI fragment has that potential 
spread much more evenly around the ring. 
Comparison of retinol’s electrostatic potential surface (Fig. 4.5B) to the other two 
suggests that retinol has a more similar potential profile to wortmannin than to PI.  The 
folded ring places the lone reactive hydrogen atom (white arrow) between two electron 
dense areas created by the hydroxyl oxygen atom (red arrow) and the pi orbitals of the 
unsaturated carbon chain (blue arrow).  The distance across this pocket is also quite 
similar to that calculated for wortmannin at approximately 3.6 Å.  It should be noted 
that the opposing purple area in Fig. 4.5B is merely due to the symmetry of the pi 
orbitals, not from a separate atom or grouping of atoms.  Previous work has shown that 
wortmannin interacts with ATP binding site of the p110 catalytic subunit of PI3K (149).  
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Therefore, based on this computational data it is feasible that retinol interacts with PI3K 
in a manner reminiscent to that of wortmannin.   
 
DISCUSSION 
Previous work in our laboratory has shown that retinol inhibited ATRA-resistant 
colon cancer cell invasion (144).  The current study demonstrates that retinol treatment 
decreases PI3K activity in both HCT-116 and SW620 ATRA-resistant human colon 
cancer cell lines (Fig. 4.1).  As little as 30 min of retinol treatment results in a 
significant decrease in PI3K activity in both cell lines.  The ability of retinol to inhibit 
PI3K activity is not due to reduced p85 regulatory subunit or p110 catalytic subunit levels 
or to a decrease in the heterodimerization of these two proteins (Fig. 4.2).  Rather, 
retinol treatment decreases PI3K activity by inhibiting PI3K and PI interaction (Fig. 4.3) 
in purified preparations of PI3K obtained by immunoprecipitation of this enzyme from 
non-retinol-treated cells.  Furthermore, both retinol and LY294002 decrease cell 
invasion (Fig. 4.4).  Finally, retinol and the PI3K inhibitor, wortmannin, exhibit similar 
electrostatic potential surfaces (Fig. 4.5).  Taken together, these data suggest that retinol 
decreases the invasion of colon cancer cells by inhibiting PI3K, potentially in a manner 
similar to that of wortmannin.  
To our knowledge, this study is the first to show that retinol inhibits PI3K 
activity.  Several studies have shown that ATRA, a metabolite of retinol, alters PI3K 
activity.  However, the direction of the affect depends on cell type.  For example, 
ATRA increased PI3K activity in SH-SY5Y human neuroblastoma (141,150), NIH3T3 
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mouse fibroblast (151), cultured vascular endothelial (140), HL-60 human promyelocytic 
leukemia (152-154) and human myeloid leukemia cells (155).  In contrast, ATRA 
decreased PI3K activity in vascular smooth muscle cells (143) and decreases Akt activity, 
a target of PI3K, in F9 murine teratocarcinoma cells (156), the breast cancer cell lines 
MCF-7, SKBR3 and ZR-75 (157), and in the head and neck cancer cell line, SqCC/Y1 
(158).   
The effect of ATRA on PI3K activity has been shown to be mediated by RAR.  
For example, the effect of ATRA on Akt activity was not observed in RARγ-null F9 cells 
(158).  Interestingly, RARα has been shown to bind with p85 in vascular smooth muscle 
cells (143).  However, the ability of retinol to inhibit PI3K is not RAR-dependent 
because the cell lines used in the current study lack some or all RAR (31,159-161) and 
retinol is not a ligand for RAR.  In addition, the SW620 cell line did not convert retinol 
to ATRA and the HCT-116 cell line synthesized only very small amounts of ATRA from 
retinol (162).  The small amount of ATRA made by the HCT-116 cell line did not 
activate RAR (162).  In support the RAR-independent effects of retinol on PI3K 
activity, previous work from our laboratory showed that the ability of retinol to inhibit 
cell invasion (144) and cell growth (162) was RAR-independent.  In addition, here we 
demonstrate that retinol decreases the activity of PI3K purified from non-retinol treated 
cells by immunoprecipitation indicating that retinol itself, not a metabolite, inhibits PI3K 
activity.  
Transfection of MTSV1-7 breast epithelial cells with CRBP-I inhibited PI3K 
activity by decreasing p85 phosphorylation resulting in decreased p85 and p110 
heterodimerization (142).  Phosphorylation of p85 promoted p85 and p110 association 
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and inhibiting p85-p110 association decreased PI3K/Akt signaling (142).  In the present 
study, we measure PI3K activity directly and show that retinol does not decrease p110 or 
p85 levels or the interaction between these two proteins to reduce PI3K activity (Fig. 
4.2).  p85 phosphorylation levels were not examined because a decrease in p85 
phosphorylation would be reflected in lower p85 and p110 heterodimerization.  No 
retinol was added to the cell culture medium in the study by Farias et al. (142) other than 
that present in the calf serum supplement.  We cannot rule out the possibility that 
CRBP-I is involved in the ability of retinol to inhibit PI3K.  However, CRBP-I inhibits 
p85 phosphorylation resulting in decreased p85/p110 binding (142) and p85/p110 binding 
was not affected by retinol in the present study.  Also, because retinol inhibits the 
activity of purified PI3K, we believe that while CRBP-I is present in HCT-116 cell line 
(163), CRBP-I might merely supply retinol, facilitating the inhibition of PI3K, rather than 
playing a regulatory role. 
The PI3K gene is often overexpressed or mutated contributing to tumor 
progression in breast, colon, and several other cancers [For a review please see: (22)].  
In addition, PI3K regulates multiple signaling components for tumorigenesis including 
cytoskeletal organization, metastasis, invasion, and angiogenesis [For a review please 
see: (164)].  The ability of LY294002 to decrease the invasion of ATRA-resistant colon 
cancer cell lines indicates that the PI3K signaling pathway is involved in the invasion of 
these cells (Fig. 4.4).  Other studies have also shown (149) that inhibition of PI3K 
activity suppressed the invasion and metastasis of cancer cells.  For example, Bikunin 
decreased human ovarian cancer cell metastasis and invasion through suppression of 
PI3K (165).  Down regulation of the PI3K/Cdc42/Rac 1 signaling pathway by Emodin 
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also correlated with suppression of tumor cell migration (166).  In addition, Topotecan 
inhibited vascular endothelial cell migration through inhibition of the PI3K/Akt signaling 
pathway (167).  
PI3K is an attractive target for drug development to increase apoptosis, decrease 
proliferation and block tumor progression [For a review please see:(168,169)].  Ab inito 
and molecular dynamics calculations revealed that retinol and wortmannin exhibit similar 
electrostatic potential surfaces (Fig. 4.5).  Importantly, wortmannin also suppresses PI 
binding to p110 (170), in a manner similar to that observed for retinol (Fig. 4.3).  
However, it should be noted that this computational modeling does not strictly discount 
the possibility that retinol interacts directly in the substrate binding domain of p110 in a 
manner similar to that of PI.  Further computational investigation culminating in a large 
scale docking study would be required to provide more conclusive proof.  Instead, these 
results simply support the possibility that an alternate binding method for retinol to PI3K 
may exist and that there are significant electrostatic similarities between retinol and the 
known PI3K inhibitor, wortmannin. 
In conclusion, the present study shows that retinol decreases PI3K activity by 
decreasing the interaction between PI3K and PI.  Activation of the PI3K/Akt pathway 
contributes to tumor metastasis and resistance to chemotherapy [for a review please see, 
(171)].  Treatment of ATRA-resistant colon cancer cell lines with retinol or a PI3K 
inhibitor resulted in decreased cell invasion indicating that retinol may reduce cell 
invasion by inhibiting PI3K activity.  Because elevated retinol levels can be achieved in 
the colonic lumen and liver via dietary vitamin A supplementation, retinol, or a synthetic 
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FIGURE 4.1.  RETINOL DECREASES PI3K ACTIVITY.  Total protein was isolated from 
HCT-116 (A) and SW620 (B) cells treated with 0 (vehicle control), 1, or 10 μM retinol 
for 30 min after 24 h of serum starvation.  PI3K was immunoprecipitated using IRS-1 
antibody as described in the Materials and Methods section.  Immunoprecipitated PI3K 
was incubated with PI for 10 min followed by incubation with [γ-32P] ATP for 20 min.  
Following incubation, the lipids were extracted and separated by TLC.  PI3K activity 
was normalized to total PI3K protein.  Total PI3K was detected using p85 antibody. 
 Total PI3K protein was normalized to β-actin.  Data are reported as mean ± SEM, of 








FIGURE 4.2.  RETINOL DOES NOT CHANGE P110 OR P85 PROTEIN LEVELS OR 
P85/P110 HETERODIMERIZATION. 
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FIGURE 4.2.  RETINOL DOES NOT CHANGE P110 OR P85 PROTEIN LEVELS OR 
P85/P110 HETERODIMERIZATION.  Total protein was isolated from HCT-116 (A and 
B) and SW620 (D and E) cells treated with 0 (vehicle control), 1, or 10 μM retinol for 30 
to 240 min after 24 h of serum starvation.  p85 and p110 levels were detected using p85 
and p110 antibodies as described in the Materials and Methods section.  β-Actin was 
used as an internal loading control.  Total protein was isolated from HCT-116 (C) and 
SW620 (F) cells treated with 0 (vehicle control) or 10 μM retinol for 5 to 120 min after 
24 h of serum starvation.  Total protein was immunoprecipitated using p110 antibody 
and sepharose 4A beads and detected using p85 antibody as described in the Materials 
and Methods section.  Immunoprecipitated p110 was detected using p110 antibody and 




FIGURE 4.3.  RETINOL DECREASES PI3K ACTIVITY BY INHIBITING PI3K AND PI 
INTERACTION. 
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FIGURE 4.3.  RETINOL DECREASES PI3K ACTIVITY BY INHIBITING PI3K AND PI 
INTERACTION.  Total protein was isolated from HCT-116 (A and C) and SW620 (B) 
cells treated with 10% FBS for 30 min after 24 h of serum starvation.  Total PI3K was 
immunoprecipitated using p110 antibody as described in the Materials and Methods 
section.  Immunoprecipitated PI3K was incubated with increasing concentrations of 
retinol and 10 μg PI for 10 min and then incubated with [γ-32P] ATP for 20 min (A and 
B).  Immunoprecipitated PI3K was incubated with increasing concentrations of PI and 
10 μg retinol for 10 min and then incubated with [γ-32P] ATP for 20 min (C).  Total 
immunoprecipitated PI3K was detected by p110 antibody and used as an internal loading 
control.  Following incubation the lipids were extracted and separated by TLC as 
described in the Materials and Methods Section.  Data are reported as mean ± SEM, of 




FIGURE 4.4.  RETINOL AND LY294002 DECREASE CELL INVASION.  HCT-116 (A) 
and SW620 (B) cells were serum starved for 24 h before seeding at a density of 1 x 105 
cells/well on Matrigel-coated Boyden chambers.  The upper portion of the chambers 
contained 0 or 10 μM retinol or 0, 10 or 50 μM LY294002 in serum free media.  The 
lower chamber contained media supplemented with 10% FBS to serve as a 
chemoattractant.  Cell invasion was measured after 24 h as described in the Materials 
and Methods section.  Data are reported as mean ± SEM, of three independent 
experiments.  *Significantly different from control (P < 0.05). 
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FIGURE 4.5.  RETINOL AND WORTMANNIN EXHIBIT SIMILAR ELECTROSTATIC 
POTENTIAL SURFACES. 
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FIGURE 4.5.  RETINOL AND WORTMANNIN EXHIBIT SIMILAR ELECTROSTATIC 
POTENTIAL SURFACES.  Electrostatic potential surfaces for (A) wortmannin, (B) retinol 
and (C) a PI fragment were calculated as described in the Materials and Methods section.  
In all three panels purple wire frames indicate areas of negative electrostatic potential 
whereas green indicates positive potential.  Surfaces are shown over a tube structure for 
the conformation with carbon atoms in blue, oxygen atoms in red, hydrogen atoms in 
white and phosphorus atoms in yellow.  Arrows indicate areas associated with either 
reactive hydrogen atoms (white) or moieties responsible for largely negative electrostatic 
potential (red and blue). 
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Chapter 5:  Dietary Vitamin A Decreases Liver Metastases of Colon 
Cancer in Mice  
ABSTRACT 
Previously, we showed that retinol inhibited all-trans-retinoic acid (ATRA)-
resistant human colon cancer cell invasion via a retinoic acid receptor-independent 
mechanism in vitro.  The objectives of the current study were to determine if dietary 
retinol inhibited metastasis of ATRA-resistant colon cancer cells in a nude mouse 
xenograft model.  HCT-116, ATRA-resistant human colon cancer cells, were 
intrasplenically injected into female nude mice (BALB/cAnNCr-nu/nu).  Injection of 
tumor cells resulted in the establishment of a splenic tumor which then shed cells that 
metastasized to the liver.  Supplemental dietary vitamin A as retinyl palmitate was 
provided after injection for 5 wks in the chemotherapy study and for one month prior to 
and 5 wks after injection for the chemoprevention study.  Consumption of a diet 
containing 200,000 IU vitamin A /kg diet decreased tumor incidence in the chemotherapy 
study and tumor multiplicity in the chemoprevention study.  Supplementation with 
200,000 IU vitamin A/kg diet decreased tumor incidence to 45.2% (P = 0.14) and tumor 
multiplicity to 17% (P = 0.03) of control in the chemotherapy and chemoprevention 
studies, respectively.  Thus, supplemental dietary vitamin A may be an effective 





Colorectal cancer is the third most common cancer and cause of death due to 
cancer in the United States.  Death due to colorectal cancer is generally caused by 
distant metastasis rather than the primary tumor itself (7).  Many cancers metastasize to 
specific organs [For a review please see: (172)].  For example, colon cancer mainly 
metastasizes to the liver and lungs (172).  The diet contains (1) preformed vitamin A as 
retinyl esters in animal-derived food sources and (2) provitamin A carotenoids in plant-
derived food sources.  Once absorbed, retinol is re-esterified and transported to the liver, 
the major site of vitamin A storage, via chylomicrons.  Hepatic retinol levels increase in 
response to supplementation and values in excess of 90 μM have been reported (44).  
Therefore, dietary vitamin A supplementation can increase retinol levels in the colon and 
liver, potentially affecting both primary colon tumors and those that have metastasized to 
the liver. 
The retinoids, a group of compounds consisting of vitamin A (retinol), its natural 
metabolites and several synthetic compounds, have also been shown to inhibit metastasis 
in a variety of model systems.  For example, dietary retinyl palmitate decreased 
malignant melanoma metastasis in mice (86).  ATRA decreased breast cancer (105), 
gastric cancer (87) and colon cancer cell invasion (88) in vivo and rhabdomyosarcoma 
metastasis in rats (135).  Also, retinol decreased hepatic metastases in a hamster model 
of pancreatic ductal carcinoma (173).   Previously, we showed that retinol decreased the 
growth and invasion of ATRA-resistant human colon cancer cells via a novel RAR-
independent mechanism in vitro (144,162,174).   
 100
Recent studies in our laboratory showed that retinol decreases MMP-2, -9 and 
PI3K activity to inhibit cancer cell invasion in vitro (144,174)  In addition, nude mice 
studies bearing colon cancer cells to generate liver metastasis showed that down 
regulation of these proteins was associated with regression of cancer progression.  For 
example, interferon-α administration to nude mice following intrasplenic injection with 
human colon cancer cells (KM12L4) showed a decrease in MMP-9 and basic fibroblast 
growth factor (bFGF) levels in liver metastatic tumors and reduced liver metastasis 
incidence (175).  PI3K specific siRNA treatment suppressed the hepatic metastases of 
colon cancer cells injected intrasplenically (176).  On the other hand, an HCT-116 
mutant cell line expressing constitutively active PI3K promoted liver metastases in 
orthotopically implanted nude mice than when compared to nude mice implanted with 
wild type HCT-116 cells (24). 
The objectives of the present study were to determine if dietary vitamin A 
supplementation decreased the hepatic metastases of colon tumor cells in vivo.  Liver 
metastases were induced by intrasplenic injection of wild type HCT-116 human colon 
carcinoma cells into female BALB/cAnNCr-nu/nu nude mice.  Hepatic tumor incidence 
and multiplicity were measured to examine the effect of dietary vitamin A 
supplementation.  MMP-2, -9 and phospho-Akt levels were also examined to determine 
the mechanism by which dietary vitamin A reduces liver metastasis in vivo. 
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MATERIALS AND METHODS 
Tissue Culture 
The human colorectal carcinoma cell line, HCT-116 was obtained from the 
American Type Culture Collection (Manassas, VA) and grown in DMEM in a humidified 
atmosphere at 37°C with 5% CO2.  Media were supplemented with 10% FBS (fetal 
bovine serum) and antibiotics (1000 U/mL penicillin and 1000 μg/mL streptomycin).   
 
Animal Studies 
This animal study was performed in accordance with the principles and 
procedures outlined in the National Institutes of Health Guide for the Care and Use of 
Laboratory animal under assurance number A4107-01 and with the University of Texas 
IACUC, protocol number 05060201.   
Metastasized liver tumors were generated by intrasplenic injection of 2 x 106 
HCT-116 cells in 50 μl of magnesium and calcium free HBSS into female 
BALB/cAnNCr-nu/nu mice (Strain code 01B70, NCI-Frederick, Frederick, Maryland).  
Purified AIN-76 rodent diet was modified to contain different concentration of retinyl 
palmitate and irradiated (Research Diets, Inc).  This modified AIN-76 diet contains 
2,400 (control-meets National Research Council (NRC) mouse vitamin A requirement 
(177)), 12,000, 25,000, 50,000, 100,000 or 200,000 IU vitamin A/kg diet as retinyl 
palmitate.  Diet compositions are described in Table 5.1.  Diets were stored at 4 °C in 
black painted containers.  Diets and water were consumed ad libitum.  Fresh diets were 
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provided every other day and feed consumption was recorded at this time.  The mice 
were weighed weekly. 
Chemotherapy experiment:  
After tumor cell injection, mice (n=15 per group) aged 6 to 8 weeks were 
randomly assigned to diets containing 2,400, 12,000, 25,000, 50,000, 100,000 or 200,000 
IU vitamin A/kg diet as retinyl palmitate.  These diets provided 1, 5, 10, 20, 40 and 80 
X the daily vitamin A requirement of mice.  Diets were supplied immediately after 
surgery and consumed for five weeks, until sacrifice. 
Chemoprevention experiment:  
Mice (n=14 per group) between aged 6 to 8 weeks were fed either the 2,400 IU 
vitamin A/kg control diet or a diet containing 200,000 IU vitamin A/kg diet as retinyl 
palmitate for four weeks before surgery.  After surgery, the mice consumed the same 
diets for five more weeks prior to sacrifice to examine liver metastases. 
 
Immunohistochemistry 
Livers were extracted, fixed with 10% buffered formaldehyde and paraffin-
embedded.  Cytokeratin (CK) 20 (sc-17113, Santa Cruz Biotechnology, Santa Cruz, 
CA), a protein expressed in human goblet cells and enterocytes (178), was used to detect 
metastasized human colon cancer cells in paraffin-embedded liver sections.  For the 
chemotherapy experiment, two random slides were stained with CK 20 from each liver to 
determine the presence of microscopic liver metastasis of colon cancer cells.  If both 
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slides showed negative staining, four more random slides were selected and stained with 
CK20 to confirm negative staining.   
MMP-2 (AB19167, Chemicon, Temecula, CA), MMP-9 (AB16306-50, Abcam, 
Cambridge, MA), total Akt (#4691, Cell Signaling, Beverly, MA), and phospho-Akt (Ser 
473) (sc-7985-R, Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were also used 
for immunohistochemistry.  Three consecutive 4 μm sections were stained with CK20, 
MMP-2, and MMP-9 or CK20, total Akt, and phospho-Akt in this order.  Tissue 
sections were deparaffinized in xylene, and rehydrated in descending ethanol series to 
water.  Next, endogenous peroxidase was blocked by incubating with 3% hydrogen 
peroxide for 10 min.  Antigen retrieval was performed by heating tissue sections in 10 
mM citrate buffer (pH 6.0) for 10 min in a microwave followed by a 20 min cool down.  
Non-specific antibody binding was blocked with Biocare Blocking Reagent (BS966M, 
Biocare, Phoenix, AZ) for 10 min.  A 1:100 dilution of CK20, a 1:100 dilution of MMP-
2, a 1:500 dilution of MMP-9, a 1:100 dilution of total Akt and a 1:50 dilution of 
phospho-Akt were used for primary antibody incubation.  The samples were then 
incubated with horseradish peroxidase conjugated anti-rabbit (#RMR622, Biocare, 
Concord, CA) or anti-goat (#GHP516L, Biocare) secondary antibodies.  The slides were 
the counterstained, mounted and observed by light microscopy.  All 
immunohistochemistry was performed by the Histology & Tissue Processing Facility 




Values shown are the mean ± SEM.  Statistical tests other than tumor incidence 
were performed using SPSS (Apache Software Foundation, Wilmington, DE, version 
12.0 for Windows).  Fisher’s exact test was used for the statistical analysis for tumor 
incidence.  Body weight, food intake, and tumor multiplicity were analyzed using two-
tailed t-tests comparing each vitamin A concentration to control (2,400 IU/kg).  Results 




Food intake and Body Weight Analysis 
At the beginning of the chemotherapy study, each group of mice (n=15 per group) 
had a mean body weight of 17.7 ± 0.02 g.  Five weeks after tumor injection, the average 
body weight of the group consuming the diet containing 200,000 IU vitamin A/kg (17.7 ± 
0.01 g) diet was less than that of the mice consuming the control diet (19.4 ± 0.12 g) (Fig. 
5.1A).  After consuming the diets for nine weeks, there were no significant differences 
in body weight between control mice, and those consuming 200,000 IU vitamin A/kg diet 
in the chemoprevention study.  No mice in the chemoprevention study lost weight; both 
groups gained 4.8 ± 0.13 g of body weight.  However, most weight gain was before 
tumor injection. 
There were no differences in food intake among the different dietary groups for 
both the chemotherapy and chemoprevention experiments.  However, the amount of 
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food intake decreased after tumor injection in both experiments (Fig. 5.1 B and D).  In 
addition, only one mouse in the chemotherapy study, consuming 200,000 IU vitamin 
A/kg diet, showed skin redness and desquamation.  No mice in the chemoprevention 
study showed any signs of vitamin A toxicity.  These data show that high levels of 
vitamin A supplementation do not adversely affect body weight and food intake or cause 
toxicity in mice. 
 
 The effect of retinol on liver metastases incidence in the chemotherapy study. 
Because visible metastases were not always apparent and to confirm that the 
visual metastases were indeed true metastases of human origin, liver sections were 
subjected to immunohistochemical analysis for the presence of CK 20, a marker of 
human colon cells.  This also allowed us to visualize micrometastases.  As can be seen 
in Fig. 5.2A, dietary supplementation with 50,000, 100,000 or 200,000 IU vitamin A/kg 
diet decreased the incidence of metastasis.  The number of metastases per dietary group 
is displayed in Table 5.2.  The greatest degree of inhibition was achieved by the 
consumption of the 200,000 IU vitamin A/kg diet.  These mice exhibited a metastasis 
rate 45.2% less (P = 0.14) than that exhibited by mice consuming the control diet (Table 
5.2 and Fig. 5.2C).  These data indicate that dietary supplementation with vitamin A 
trends to inhibit the metastases of human colorectal cancer cells in a nude mouse 
xenograft chemotherapy model, confirming our in vitro observations. 
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The effect of retinol on tumor multiplicity in chemoprevention study. 
Because the incidence of metastasis was very high and visual tumors were 
apparent in the chemoprevention study, we determined metastasis multiplicity, defined 
here as the number of metastatic tumors per liver, per mouse.  Supplementation with 
200,000 IU vitamin A/kg diet significantly reduced tumor multiplicity from 56.57 ± 
21.99 to 9.86 ± 3.8 (P = 0.03) (Fig. 5.3) which decreased tumor multiplicity to 17% of 
control.  These data indicate that dietary vitamin A supplementation, prior to tumor cell 
injection, reduces the number of metastases per liver. 
In a previous study, we showed that retinol decreased MMP-2, -9 and PI3K 
activity resulting in inhibition of human colon cancer cell invasion in vitro (144,174).  
To determine if the activity of these enzymes were decreased by dietary vitamin A 
supplementation, liver metastases were stained with MMP-2, -9, total Akt, and phospho-
Akt.  Phospho-Akt corrected for total Akt represents PI3K activity.  These four 
antibodies were pre-examined for positive staining in different tissues (data not shown).  
Liver metastases introduced by intrasplenic injection of human colon cancer cells showed 
no staining for MMP-2 and -9 (Fig. 5.4 B and C).  Metastasized tumors showed positive 
total and phospho-Akt staining.  However, vitamin A supplementation did not change 
the level of total or phospho-Akt (Fig. 5.4 D to F). 
 
DISCUSSION 
The liver is the major storage site for vitamin A and the target organ for colon 
cancer metastasis.  Previously, we showed that retinol decreased ATRA resistant colon 
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cancer cell growth and invasion in vitro (144,162,174).  Here, we demonstrate that 
200,000 IU vitamin A/kg diet decreased the incidence and multiplicity of liver metastases 
in nude mice intrasplenically injected with ATRA-resistant human colon cancer cells 
(Table 5.2, Fig.5.2 and Fig. 5.3).  Previously, we showed that retinol decreased ATRA-
resistant colon cancer invasion by inhibiting MMP-2, -9 and PI3K activity in vitro 
(144,174).  However, MMP-2 and -9 were not expressed by liver metastases and PI3K 
activity in liver metastases was not changed by dietary vitamin A supplementation 
(Figure 5.3). 
The recommended daily allowance (RDA) levels for vitamin A is 2333 IU/day for 
female adult humans (over age 14) (179).  Daily ingestion of over 100,000 IU (33.3X 
the RDA) for more than six months is considered toxic [For a review please see; (180)].  
In addition, the smallest daily vitamin A uptake reported to cause liver cirrhosis was 
25,000 IU (10X the RDA) for six years (181).  The recommended vitamin A dietary 
level from the NRC for mice is 2,400 IU of vitamin A/kg of diet (182).  The diets used 
in this study contain 2,400 (1X NRC), 12,000 (5X NRC), 25,000 (10X NRC), 50,000 
(20X NRC), 100,000 (40X NRC) and 200,000 (80X NRC) IU vitamin A/kg diet.  
However, only 200,000 IU/kg tended to decrease tumor incidence and significantly 
decreased tumor multiplicity in the chemotherapy and chemoprevention studies, 
respectively.  If the NRC recommendation for mice is proportional to the RDA for 
humans, only 12,000 IU/kg is in the safe range for vitamin A toxicity.  The amount of 
vitamin A which showed adverse effect (200,000 IU/kg, 80X RDA) on liver metastasis 
might be harmful for humans.  There is a study showing that ingestion of 200,000 IU 
(87X NRC) vitamin A/kg diet decreased aberrant crypt foci incidence in rat (2300 IU/kg 
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– NRC rat vitamin A requirement) (45).  However, this study did not mention anything 
concerning toxicity caused by 200,000 IU/kg of vitamin A supplementation.  We did not 
use different diets between 12,000 and 100,000 IU/kg in the chemoprevention study.  
Therefore, it is possible that a lower level of vitamin A supplementation would show the 
same effect as 200,000 IU/kg vitamin A supplementation and decreases metastasis 
multiplicity in chemoprevention study. 
Although dietary vitamin A decreased tumor incidence in chemotherapy study, 
the tumor incidence in the chemoprevention study was 100% regardless of vitamin A 
supplementation level.  It is important to note that different cell preparations were used 
for the two dietary experiments, therefore direct comparisons between experiments may 
not be possible.  In each case, the viability of the HCT-116 cell suspension was assessed 
before and after surgery via trypan blue dye exclusion assay.  Cell viability following 
surgery was > 92% in both cases.  We believe the higher incidence of metastasis in the 
chemoprevention experiment most likely reflects the cell preparation injected.  
Alternatively, Vitamin A might show a different effects depending on time administered 
relative to tumor injection.  For example, folate, a promising micronutrient for colon 
cancer prevention, inhibits the initiation of colon cancer progression (28).  However, 
folate deficiency also reduces the size of colon cancer tumors (28), indicating that the 
same nutrient can show two different effects depending on the stage of colon cancer.  
Therefore, it is possible that preloading vitamin A in the liver might promote tumor 
progression but decrease tumor growth. 
We previously showed that retinol decreased the invasion of ATRA-resistant 
human colon cancer cells by decreasing MMP-2, -9 and PI3K activity in vitro.  
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However, we did not observe MMP-2 and -9 staining in the metastatic liver tumors in the 
current study.  These tumors were derived from the same cell line, HCT-116, used our 
in vitro study.  We hypothesized that the effect of vitamin A on the activity of these 
proteins may be dependent upon stage of metastasis.  For example, MMP-2 and -9 may 
required at the beginning of liver metastases.  Therefore, mice may need to be sacrificed 
at an earlier time point to determine changes in MMP-2 and -9 protein levels in response 
to dietary vitamin A supplementation.   
We detected phospho-Akt staining in liver metastases of human colon cancer 
cells, however, the level of phospho-Akt was not changed by vitamin A supplementation.  
Rychahou et al showed that inhibition of PI3K subunits, either p85 or p110, using siRNA 
decreased tumor multiplicity (176).  In the Rychahou et al study, they also examined the 
expression of Akt1 and Akt 2.  In human, there are three isoforms of Akt, designated 
Akt1, 2, and 3.  Previous studies showed increased Akt 1 and 2 activation in colorectal 
cancers and colon cancer cell lines (183,184).  The Rychahou et al study showed Akt1 
expression was highly variable but increased expression of Akt 2 was found in all human 
colorectal cancers especially in the late stage of cancers.  Samuels et al showed that 
Akt1 is the predominant form of Akt in HCT-116 cells (185).  However, Bruzek et al 
showed expression of both Akt 1 and 2 in the same cell line (186).  Akt3 expression has 
not been studied in this cell line.  The contribution of Akt1 and Akt2 to cell invasion is 
currently unclear in the HCT-116 cell line.  Both total and phospho-Akt antibody used 
in this study detect all three types of Akt.  Therefore, we might not detect the changes of 
activation of the specific isoform of Akt which is important for liver metastasis of colon 
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cancer.  Therefore, determination of the Akt isoform required for invasion should occur 
before additional investigation of PI3K activity in liver metastasis. 
In conclusion, the present study shows that dietary vitamin A supplementation 
decreases tumor incidence in mice subjected to a chemotherapy dietary regimen and 
tumor multiplicity in mice subjected to chemoprevention regimen.  However, the 
inhibition of MMP-2, -9 and PI3K activity by retinol treatment showed in our previous in 
vitro studies was not observed here.  To our knowledge, this study is the first to show 
that dietary vitamin A supplementation inhibits colon cancer metastasis to the liver in a 
mouse model.  Taken together, these data suggest the possibility of dietary vitamin A 
supplementation for colon cancer therapy and prevention. 
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Table 5.1.  Diet composition 
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Table 5.2.  Dietary vitamin A content versus incidence of metastases 
Dietary Vitamin A 
(IU/kg diet) 
Number of mice 
/group with metastases 
Tumor incidence 
(% of control) 
2,400 (control) 10/15  100 
12,000 11/15 (P = 1.00) 110 
25,000 11/15 (P = 1.00) 110 
50,000 8/15 (P = 0.71) 72.6 
100,000 8/15 (P = 0.71) 72.6 




FIGURE 5.1.  AVERAGE FOOD INTAKE AND BODY WEIGHT.  Average body weight for 
5 weeks on vitamin A supplemented diets of the chemotherapy study (A) and for 9 weeks 
on diets of the chemoprevention study (B).  Average food intake for the chemotherapy 
study (C) and the chemoprevention study (D).  Mice were fed with 2,400 (♦), 12,000 
(▲), 25,000 (●), 50,000 (X), 100,000 (*), and 200,000 ( ) IU vitamin A/kg diet in the 
chemotherapy and 2,400 (♦), and 200,000 ( ) IU vitamin A/kg diet in the 
chemoprevention sutdy.  Data shown are mean ± SEM [n=15 (A and B) and n=14 (C 
and D)].  *Significantly different from control (P < 0.05). 
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FIGURE 5.2.  DIETARY VITAMIN A SUPPLEMENTATION DECREASES METASTATIC 
INCIDENCE; CHEMOTHERAPY DIETARY MODEL.  Ninety female BALB/cAnNCr-
nu/nu mice, aged 6 to 8 wks, were intersplenically injected with 2 x 106 HCT-116 cells 
in 50 μl of magnesium and calcium free HBSS.  Immediately following surgery the 
mice were divided into six groups (n=15 per group) and consumed diets containing 
increasing amounts of vitamin A as retinyl palmitate.  Five weeks following surgery, all 
mice were sacrificed and the incidence of liver metastases assessed by cytokeratin 20 
staining, (A) Negative (from normal liver) and (B) positive (liver metastases) CK 
staining.  Dietary supplementation with 50,000, 100,000 or 200,000 IU vitamin A/kg 




FIGURE 5.3.  DIETARY VITAMIN A SUPPLEMENTATION REDUCES TUMOR 
MULTIPLICITY IN MICE SUBJECTED TO THE CHEMOPREVENTION DIETARY REGIMEN.  
BALB/cAnNCr-nu/nu female mice, aged 6 to 8 wks, were randomly divided into two 
groups.  The first group consumed the control diet, containing 2,400 IU vitamin A/kg 
diet.  The second group consumed a diet supplemented with 200,000 IU vitamin A/kg 
diet.  The mice consumed these diets ad libitum for one month prior to surgery.  To 
generate metastases, the mice were intersplenically injected with 2 x 106 HCT-116 cells 
in 50 μl of magnesium and calcium free HBSS.  Following surgery, the mice continued 
to consume their respective diets for five weeks.  After five weeks, all mice were 
sacrificed and their livers examined visually for the presence and number of metastases.  





FIGURE 5.4.  IMMUNOHISTOCHEMICAL DATA FROM CHEMOPREVENTION STUDY.  
Consecutive slides of liver metastatic tumor were stained with CK20, MMP-2, and 
MMP-9 (A).  In addition, consecutive slides of liver metastasis sample were stained 
with CK20, total Akt, and phospho-Akt (B).  One representative sample is shown.  The 
level of active Akt was not altered by vitamin A supplementation (C).  Data shown are 
mean ± SEM, n=5. 
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Chapter 6:  Summary and Future Directions 
Colorectal cancer is the third most common cancer in the USA.  Early diagnosis 
and treatment helps decrease the five year survival rate for patients with colorectal 
cancer.  However, colorectal cancer is still the third leading cause of cancer death in the 
USA.  Moreover, distant metastases of colon cancer are more problematic.  These facts 
indicate that we need more effective treatment for colon cancer.  In addition, many 
studies have been conducted to show that micronutrients reduce colon cancer incidence 
and progression.  We focused on the effect of retinol on colon cancer progression 
because colonocytes are primarily exposed to retinol from the diet.  Chapter 1 
introduced the importance of inhibiting human colon cancer cell growth and metastasis.  
It also provided the reasons to study the effect of retinol on colon cancer growth and 
metastasis instead of other bioactive retinoids such as ATRA. 
Chapter 2 showed that retinol inhibited the growth of both ATRA-sensitive and 
ATRA-resistant human colon cancer cell lines independent of the ATRA/RAR/RARE 
retinoid signaling pathway.  First, retinol was not metabolized to other bioactive 
retinoids, such as ATRA.  Second, retinol did not activate RARE-mediated gene 
transcription.  Finally, a RAR-antagonist blocked the ability of ATRA to inhibit the 
growth of ATRA-sensitive HCT-15 cells, as expected, but did not block the ability of 
retinol to inhibit the growth of any cell line examined.  Therefore, even in the presence 
of functioning RAR, retinol did not inhibit cell growth by the actions of its metabolite 
ATRA, because this metabolite is not present in ATRA-sensitive HCT-15 cells.  In 
addition, retinol acted through a novel mechanism to inhibit the growth of both ATRA-
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sensitive and ATRA-resistant colon cancer cells by affecting cell cycle progression.  In 
Chapter 2, retinol also decreased tumor cell growth by inducing G0/1 arrest in three of the 
cell lines examined. 
These results suggest future directions concerning the molecular mechanisms 
underlying retinol’s ability to arrest the cell cycle independent of RAR/RXR/RARE and 
inhibit cancer cell growth.  Progression from G0/1 to S phase is mediated by cyclins D 
and E and cyclin dependent kinases (Cdk) 2, 4 and 6.  Cyclin-Cdk complexes are 
influenced by several cell cycle regulatory proteins such as protein kinases and 
phosphatases that modify Cdks, the cyclin dependent kinase inhibitors (CKIs); p27, p21 
and p16, and regulatory proteins such as p53 and E2F.  Unfortunately, the effect of 
retinoids on cell cycle regulatory proteins appears to be cell type specific (30).  For 
example, cyclin D1 was responsible for G1 arrest in carcinogen-exposed immortalized 
human bronchial epithelial cells (68,69).  In contrast, decreased phosphorylation of pRB 
was the major factor for G0/1 arrest in MCF-7 breast cancer cells (70-72).  We have seen 
that inhibition of invasion by retinol treatment depends on posttranslational modification 
such as phosphorylation events (Chapters 3 and 4).  However, we have not examined the 
effect of cycloheximide (translation inhibitor) and actinomycin D (transcription inhibitor) 
on retinol’s inhibitory effect on cell growth due to toxicity of these chemicals when 
treating for more than 24 hr required for retinol to show its inhibitory effect on cancer 
cell growth.  Therefore, the inhibitory effect of retinol on colon cancer cell growth is 
open to all three possibilities; (1) inhibiting mRNA or (2) protein synthesis or (3) 
inhibiting posttranslational modification.  To examine possible candidates for cell cycle 
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arrest-related proteins affected by retinol, we could used a cell cycle microarray as a start 
to narrow down target molecules. 
Chapters 3, 4 and 5 demonstrated that retinol decreased the invasion of human 
colon cancer cell lines in vitro and in vivo.  Figure 6.1 summarizes retinol’s inhibitory 
effects on colon cancer metastasis in vitro (Chapters 3 and 4).  Chapter 3 showed that 
retinol inhibited ATRA-resistant colon cell invasion by decreasing gelatinase activity and 
increasing TIMP-1 levels in vitro through an ATRA and RAR-independent mechanism.  
Chapter 4 demonstrated that retinol treatment decreased PI3K activity in ATRA-resistant 
human colon cancer cell lines.  Retinol decreases PI3K activity by acting similarly to 
the known PI3K inhibitor, wortmannin, not due to reduced p85 regulatory subunit or 
p110 catalytic subunit levels or to a decrease in the heterodimerization of these two 
proteins.  Chapter 5 showed that dietary vitamin A supplementation had both 
chemopreventive and chemotherapeutic potential to decrease liver metastases of colon 
tumor cells in a nude mice xenograft model. 
We have studied the upstream signaling molecule (PI3K) and downstream 
effecter molecules (gelatinases and TIMP-1) affected to retinol to inhibit colon cancer 
cell invasion.  However, it is necessary to link PI3K to the gelatinases and TIMP-1.  
The PI3K/Akt signaling pathway up-regulates metastasis related genes including MMP-2 
and –9 in breast cancer and colon cancer [for review see: (9,164)].  Unfortunately, the 
molecular mechanisms are not well understood between activation of PI3K and activation 
of MMP-2 and -9 activity (187,188).  Our studies showed that retinol decreased MMP-2 
and –9 activity (chapter 3) and PI3K activity (chapter 4).  Therefore, future studies 
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could investigate the molecular mechanisms or signaling pathways between PI3K and 
MMP-2 and -9 regulated by retinol that ultimately decrease cell invasion. 
In addition, we expected to see changes in protein levels of MMP-2 and -9 from 
the IHC experiment in Chapter 5.  However, MMP-2 and -9 showed negative staining in 
liver metastases.  As mentioned in the discussion in Chapter 5, MMP-2 and -9 may be 
required in the early stages of tumor metastasis.  Therefore, in a future experiment, 
tumor-injected mice should be sacrificed at earlier times to detect changes in MMP-2 and 
-9 expression.  Finally, different concentrations of vitamin A in diets between 12,000 to 
100,000 IU/kg should be used in the chemoprevention study to determine the minimum 
amount of vitamin A supplementation which will decreases liver metastasis. 
In conclusion, the first part of my work (Chapter 2) shows that retinol acts 
through a novel mechanism to inhibit the growth of both ATRA-sensitive and ATRA-
resistant colon cancer cells by affecting cell cycle progression.  In addition, the second 
part of my work (Chapters 3 to 5) concerns the ability of retinol to decrease the 
metastasis of ATRA-resistant colon cancer in vivo and in vitro.  To our knowledge, 
these studies are the first to show that retinol inhibits MMP-2 and -9 activity and PI3K 
activity to decrease cancer cell invasion in vitro.  There are many preclinical studies to 
support the inhibitory effect of vitamin A supplementation on many other types of cancer 
progression; however, this is the first study to show that vitamin A supplementation 
decreases the liver metastases of colon cancer.  My work suggests that dietary vitamin A 





FIGURE 6.1.  RETINOL DECREASES PI3K ACTIVITY AND/OR MMP-2 AND -9 
ACTIVITY AND INCREASES TIMP-1 SECRETION TO INHIBIT COLON CANCER 
METASTASIS.  Red blunt arrows indicate the inhibition and black arrows indicate 




1. American Cancer Society. (2007) Cancer Facts and Figures 2007. 
2. Lindblom, A. (2001) Curr Opin Oncol 13(1), 63-69 
3. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, 
R., and Ben-Ze'ev, A. (1999) PNAS 96, 5522-5527 
4. Grohmann, A., Tanneberger, K., Alzner, A., Schneikert, J., and Behrens, J. 
(2007) J Cell Sci  
5. Spirio, L., Olschwang, S., Groden, J., Robertson, M., Samowitz, W., Joslyn, 
G., Gelbert, L., Thliveris, A., Carlson, M., Otterud, B., and et al. (1993) Cell 
75(5), 951-957 
6. Ainsworth, P. J., Koscinski, D., Fraser, B. P., and Stuart, J. A. (2004) Clin 
Genet 66(3), 183-188 
7. Scheele, J., Stang, R., Altendorf-Hofmann, A., and Paul, M. (1995) World J 
Surg 19(1), 59-71 
8. Leeman, M. F., Curran, S., and Murray, G. I. (2003) The Journal of 
pathology. 201(4), 528-534 
9. Mook, O. R., Frederiks, W. M., and Van Noorden, C. J. (2004) Biochim 
Biophys Acta 1705(2), 69-89 
10. Collins, H. M., Morris, T. M., and Watson, S. A. (2001) British journal of 
cancer. 84(12), 1664-1670 
11. Ornstein, D. L., and Cohn, K. H. (2002) Digestive diseases and sciences. 47(8), 
1821-1830 
12. Levy, A. T., Cioce, V., Sobel, M. E., Garbisa, S., Grigioni, W. F., Liotta, L. 
A., and Stetler-Stevenson, W. G. (1991) Cancer Res 51(1), 439-444 
13. Baker, E. A., and Leaper, D. J. (2002) European journal of surgical oncology: 
the journal of the European Society of Surgical Oncology and the British 
Association of Surgical Oncology. 28(1), 24-29 
14. Chan, C. C., Menges, M., Orzechowski, H. D., Orendain, N., Pistorius, G., 
Feifel, G., Zeitz, M., and Stallmach, A. (2001) International journal of 
colorectal disease. 16(3), 133-140 
 123
15. Zeng, Z. S., and Guillem, J. G. (1996) British journal of cancer. 74(8), 1161-
1167 
16. Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., 
Driscoll, P. C., Woscholski, R., Parker, P. J., and Waterfield, M. D. (2001) 
Annu Rev Biochem 70, 535-602 
17. Achkar, C. C., Derguini, F., Blumberg, B., Langston, A., Levin, A. A., Speck, 
J., Evans, R. M., Jack Bolado, J., Nakanishi, K., Buck, J., and Gudas, L. J. 
(1996) PNAS 93, 4879-4884 
18. Luo, J., Manning, B. D., and Cantley, L. C. (2003) Cancer Cell 4(4), 257-262 
19. Shao, J., Evers, B. M., and Sheng, H. (2004) Cancer Res 64(1), 229-235 
20. Cantley, L. C. (2002) Science 296(5573), 1655-1657 
21. Vivanco, I., and Sawyers, C. L. (2002) Nat Rev Cancer 2(7), 489-501 
22. Samuels, Y., and Ericson, K. (2006) Curr Opin Oncol 18(1), 77-82 
23. Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, 
M., Jazag, A., Guleng, B., Tateishi, K., Asaoka, Y., Matsumura, M., Kawabe, 
T., and Omata, M. (2005) Cancer Res 65(11), 4562-4567 
24. Guo, X. N., Rajput, A., Rose, R., Hauser, J., Beko, A., Kuropatwinski, K., 
LeVea, C., Hoffman, R. M., Brattain, M. G., and Wang, J. (2007) Cancer Res 
67(12), 5851-5858 
25. Lamprecht, S. A., and Lipkin, M. (2003) Nat Rev Cancer 3(8), 601-614 
26. Alberts, D. S., Martinez, M. E., Roe, D. J., Guillen-Rodriguez, J. M., 
Marshall, J. R., van Leeuwen, J. B., Reid, M. E., Ritenbaugh, C., Vargas, P. 
A., Bhattacharyya, A. B., Earnest, D. L., and Sampliner, R. E. (2000) N Engl 
J Med 342(16), 1156-1162 
27. Lipkin, M., Reddy, B., Newmark, H., and Lamprecht, S. A. (1999) Annu Rev 
Nutr 19, 545-586 
28. Song, J., Medline, A., Mason, J. B., Gallinger, S., and Kim, Y. I. (2000) 
Cancer Res 60(19), 5434-5440 
29. Reddy, B. S. (2004) Int J Cancer 112(1), 1-7 
30. Niles, R. M. (2004) Mutation research. 555(1-2), 81-96 
 124
31. Freemantle, S. J., Spinella, M. J., and Dmitrovsky, E. (2003) Oncogene. 
22(47), 7305-7315 
32. Dragnev, K. H., Petty, W. J., and Dmitrovsky, E. (2003) Cancer biology & 
therapy. 2(4 Suppl 1), S150-156 
33. Vogel, S., Gamble, M., and Blaner, W. (1999) Retinoids: the biochemical and 
molecular basis of vitamin A and retinoid action, Springer-Verlag, Berlin 
Heidelberg 
34. Moise, A. R., Noy, N., Palczewski, K., and Blaner, W. S. (2007) Biochemistry 
46(15), 4449-4458 
35. Fiorella, P., Giguere, V., and Napoli, J. (1993) J. Biol.Chem. 268, 21545-21552 
36. Soprano, D., Qin, P., and Soprano, K. J. (2004) Annu. Rev. Nut. 24, 201-221 
37. Delva, L., Bastie, J.-N., Rochette-Egly, C., Kraiba, R., Balitrand, N., 
Despouy, G., Chambon, P., and Chomienne, C. (1999) Mol. Cell. Biol. 19, 
7158-7167 
38. Dong, D., Ruuska, S., Levinthal, D., and Noy, N. (1999) J. Biol. Chem. 274, 
23695-23698 
39. Lee, M., Han, S., Jiang, S., Park, J., and Kim, S. (2000) Biochem. Pharm. 59, 
485-496 
40. Nicke, B., Kaiser, A., Wiedenmann, B., Riecken, E.-O., and Rosewicz, S. 
(1999) Biochem Biophys Res Comm 261, 572-577 
41. Nicke, B., Riecken, E.-O., and Rosewicz, S. (1999) Gut 45, 51-57 
42. Sonneveld, E., Brink, C. E. v. d., Leede, B.-j. M. v. d., Roeland-Kees, 
Schulkes, A. M., Petkovich, M., Burg, B. v. d., and Saag, P. T. v. d. (1998) 
Cell Growth Differ 9, 629-637 
43. Ross, A. (1999) Vitamin A and Retinoids. in Modern Nutrition in Disease and 
Health (Shils, M., Olson, J., Shike, M., and Ross, A. eds.), 9th Ed., pp. 305-
327, Williams and Wilkins, Baltimore, MD 
44. Garcia, A. L., Ruhl, R., and Schweigert, F. J. (2005) Ann Nutr Metab 49(5), 
333-341 
45. Delage, B., Groubet, R., Pallet, V., Bairras, C., Higueret, P., and Cassand, P. 
(2004) Nutr Cancer 48, 28-36 
 125
46. Wargovich, M., Jimenez, A., McKee, K., Steele, V., Velasco, M., Woods, J., 
Price, R., Gray, K., and Kelloff, G. (2000) Carcinogenesis 21, 1149-1155 
47. Zheng, Y., Kramer, P., Lubet, R., Steele, V., Kelloff, G., and Pereira, M. 
(1999) Carcinogenesis 20, 255-260 
48. Zheng, Y., Kramer, P., Olson, G., Lubet, R., Steele, V., Kelloff, G., and 
Pereira, M. (1997) Carcinogenesis 18, 2119-2125 
49. Johnson, G. B. Cancer Is a Multi-Step Process. Txtwriter INC. 
50. Guo, X., and Gudas, L. J. (1998) Cancer Res. 58, 166-176 
51. Lane, M. A., Chen, A. C., Roman, S. D., Derguini, F., and Gudas, L. J. (1999) 
PNAS 96, 13524-13529 
52. Turowski, G., Rashid, Z., Hong, F., Madri, J. A., and Basson, M. D. (1994) 
Cancer Res. 54, 5974-5980 
53. Waliszewski, P., Waliszewska, M. K., Gupta, M., Milsom, J. W., and Hurst, 
R. E. (1997) J. Surg. Oncology-Supp. 66, 156-167 
54. Lee, M. O., and Kang, H. J. (2002) Biol Pharm Bull 25(10), 1298-1302 
55. Smith, F. R., and Goodman, D. S. (1971) J. Clin Invest. 50, 2426-2436 
56. De Leenheer, A. P., Lambert, W. E., and Claeys, I. (1982) J Lipid Res 23, 
1362-1367 
57. Eckhoff, C., and Nau, H. (1990) J Lipid Res 31, 1445-1454 
58. Wu, S., Dongmei, Z., Zhang, Z.-P., Soprano, D. R., and Soprano, K. J. (1998) 
Oncogene 17, 2839-2849 
59. Guo, X., Knudsen, B. S., Peehl, D. M., Ruiz, A., Bok, D., Rando, R. R., Rhim, 
J. S., Nanus, D. M., and Gudas, L. J. (2002) Cancer Res. 62, 1654-1661 
60. Klein, E. S., Pino, M. E., Johnson, A. T., Davies, P. J., Nagpal, S., Thacher, S. 
M., Krasinski, G., and Chandraratna, R. A. (1996) J Biol Chem 271(37), 
22692-22696 
61. Jette, C., Peterson, P. W., Sandoval, I. T., Manos, E. J., Hadley, E., Ireland, 
C. M., and Jones, D. A. (2004) J Biol Chem 279(33), 34397-34405 
62. Hoyos, B., Imam, A., Korichneva, I., Levi, E., Chua, R., and Hammerling, U. 
(2002) J Biol Chem 277(26), 23949-23957 
 126
63. O' Connell, M. J., Chua, R., Hoyos, B., Buck, J., Chen, Y., Derguini, F., and 
Hammerling, U. (1996) J Exp Med 184(2), 549-555 
64. Wu, S., Zhang, Z. P., Zhang, D., Soprano, D. R., and Soprano, K. J. (1997) 
Exp Cell Res 237(1), 118-126 
65. Maziere, S., Cassand, P., Narbonne, J. F., and Meflah, K. (1997) 
International journal for vitamin and nutrition research. Internationale 
Zeitschrift fÅr Vitamin- und ErnÑhrungsforschung. Journal international de 
vitaminologie et de nutrition. 67(4), 237-241 
66. Um, S., Han, H., Kwon, Y., Park, S., Rho, Y., Sin, H., and Park, J. (2003) Int 
J Cancer. 107, 1038-1046 
67. Ocker, M., Herold, C., Ganslmayer, M., Hahn, E. G., and Schuppan, D. 
(2003) International journal of cancer. Journal international du cancer. 
107(3), 453-459 
68. Boyle, J., Langenfeld, J., Lonardo, F., Sekula, D., Reczek, P., Rusch, V., 
Dawson, M., and Dmitrovsky, E. (1999) Journal of the National Cancer 
Institute 91, 373-379 
69. Langenfeld, J., Kiyokawa, H., Sekula, D., Boyle, J., and Dmitrovsky, E. 
(1997) PNAS 94, 12070-12074 
70. Teixeira, C., and Pratt, M. A. C. (1997) Mol Endo 11, 1191-1202 
71. Zhou, Q., Stetler-Stevenson, M., and Steeg, P. (1997) Oncogene 15, 107-115 
72. Zhu, W., Jones, C., and al., A. K. e. (1997) Exp Cell Res 234, 293-299 
73. Imam, A., Hoyos, B., Swenson, C., Chua, R., Levi, E., Viriya, E., and 
Hammerling, U. (2000) FASEB Journal Online 10 
74. Korichneva, I., and Hammerling, U. (1999) J Cell Sci 112, 2521-2528 
75. Korichneva, I., Waka, J., and Hammerling, U. (2003) J Pharm  Exp Therap 
305(2), 426-433 
76. Oridate, N., Suzuki, S., Higuchi, M., Mitchell, M. F., Hong, W. K., and 
Lotan, R. (1997) J Nat Can Inst 89(16), 1191-1198 
77. Wang, H., Maurer, B. J., Reynolds, C. P., and Cabot, M. C. (2001) Cancer 
Res 61(13), 5102-5105 
78. Chen, Y. R., Zhou, G., and Tan, T. H. (1999) Molecular pharmacology. 56(6), 
1271-1279 
 127
79. Fisher, G. J., Talwar, H. S., Lin, J., Lin, P., McPhillips, F., Wang, Z., Li, X., 
Wan, Y., Kang, S., and Voorhees, J. J. (1998) J Clin Investigation 101(6), 
1432-1440 
80. Sah, J. F., Eckert, R. L., Chandraratna, R. A., and Rorke, E. A. (2002) J Biol 
Chem 277(12), 9728-9735 
81. López-Carballo, G., Moreno, L., Masiá, S., Pérez, P., and Barettino, D. 
(2002) J Biol Chem 277(28), 25297-25304 
82. Lonardo, F., Dragnev, K. H., Freemantle, S. J., Ma, Y., Memoli, N., Sekula, 
D., Knauth, E. A., Beebe, J. S., and Dmitrovsky, E. (2002) Clinical cancer 
research: an official journal of the American Association for Cancer Research. 
8(1), 54-60 
83. Ogawa, M., Ikeuchi, K., Watanabe, M., Etoh, K., Kobayashi, T., Takao, Y., 
Anazawa, S., and Yamazaki, Y. (2005) Hepato-gastroenterology. 52(63), 875-
880 
84. Pesta, M., Holubec, L., Jr., Topolcan, O., Cerna, M., Rupert, K., Holubec, L. 
S., Treska, V., Kormunda, S., Elgrova, L., Finek, J., and Cerny, R. (2005) 
Anticancer research. 25(5), 3387-3391 
85. Hornebeck, W., Lambert, E., Petitfrère, E., and Bernard, P. (2005) 
Biochimie. 87(3-4), 377-383 
86. Weinzweig, J., Tattini, C., Lynch, S., Zienowicz, R., Weinzweig, N., 
Spangenberger, A., and Edstrom, L. (2003) Plastic and reconstructive surgery. 
112(1), 152-158; discussion 159-161 
87. Qiao, W., Chen, Y., Chen, Z., Chen, F., and Su, W. (2002) Acta 
Pharmacologia Sinica 23(9), 835-841 
88. Adachi, Y., Fumio, I., Yamamoto, H., Iku, S., Matsuno, K., Arimura, Y., and 
Imai, K. (2001) Tumor Biology 22, 247-253 
89. Soprano, D. R., Qin, P., and Soprano, K. J. (2004) Annual Review of Nutrition 
24, 201-221 
90. Sonneveld, E., van den Brink, C. E., van der Leede, B. M., Schulkes, R., 
Petkovich, M., van der Burg, B., and van der Saag, P. T. (1998) Cell Growth 
Differ. 9, 629-637 
91. Nicke, B., Kaiser, A., Wiedenmann, B., Riecken, E. O., and Rosewicz, S. 
(1999) Biochem. and Biophys. Res. Comm. 21, 572-577 
92. Nicke, B., Riecken, E. O., and Rosewicz, S. (1999) Gut 45, 51-57 
 128
93. Lee, M. O., Han, S. Y., Jiang, S., Park, J. H., and Kim, S. J. (2000) 
Biochemical pharmacology. 59(5), 485-496 
94. Vogel, S., Gamble, M. V., and Blaner, W. S. (1999) Biosynthesis, absorption, 
metabolism and transport of retinoids. in Retinoids: the biochemical and 
molecular basis of vitamin A and retinoid action (Nau, H., and Blaner, W. S. 
eds.), pp. 31-95, Springer-Verlag, Berlin Heidelberg 
95. Park, E. Y., Dillard, A., Williams, E. A., Pepper, M. R., Wilder, E. T., and 
Lane, M. A. (2005) Cancer Research 65(21), 9923-9933 
96. Baugher, P. J., Krishnamoorthy, L., Price, J. E., and Dharmawardhane, S. F. 
(2005) Breast Cancer Res 7(6), R965-R974 
97. Livak, K. J., and Schmittgen, T. D. (2001) Methods: a companion to Methods 
in enzymology. 25(4), 402-408 
98. Chung, T. W., Lee, Y. C., Ko, J. H., and Kim, C. H. (2003) Cancer research. 
63(13), 3453-3458 
99. Waliszewski, P., Waliszewska, M. K., Gupta, M., Milsom, J. W., and Hurst, 
R. E. (1997) Journal of Surgical Oncology-Supplement 66(3), 156-167 
100. Klein, E. S., Pino, M. E., Johnson, A. T., Davies, P. J., Nagpal, S., Thacher, S. 
M., Krasinski, G., and Chandraratna, R. A. (1996) The Journal of biological 
chemistry. 271(37), 22692-22696 
101. Yamamoto, H., Iku, S., Adachi, Y., Imsumran, A., Taniguchi, H., Nosho, K., 
Min, Y., Horiuchi, S., Yoshida, M., Itoh, F., and Imai, K. (2003) J Pathol 
199(2), 176-184 
102. Seiler, N., Schneider, Y., Gosse, F., Schleiffer, R., and Raul, F. (2004) Int J 
Oncol 25(4), 1039-1048 
103. Jette, C., Peterson, P. W., Sandoval, I. T., Manos, E. J., Hadley, E., Ireland, 
C. M., and Jones, D. A. (2004) The Journal of biological chemistry. 279(33), 
34397-34405 
104. Wu, S., Zhang, Z. P., Zhang, D., Soprano, D. R., and Soprano, K. J. (1997) 
Experimental cell research. 237(1), 118-126 
105. Liu, H., Zang, C., Fenner, M. H., Possinger, K., and Elstner, E. (2003) Breast 
cancer research and treatment. 79(1), 63-74 
106. Lateef, H., Stevens, M. J., and Varani, J. (2004) American journal of 
pathology. 165(1), 167-174 
 129
107. Benbow, U., Schoenermark, M. P., Orndorff, K. A., Givan, A. L., and 
Brinckerhoff, C. E. (1999) Clinical & experimental metastasis. 17(3), 231-238 
108. Benbow, U., Schoenermark, M. P., Mitchell, T. I., Rutter, J. L., Shimokawa, 
K., Nagase, H., and Brinckerhoff, C. E. (1999) The Journal of biological 
chemistry. 274(36), 25371-25378 
109. Nwankwo, J. O. (2002) Anticancer research. 22(6C), 4129-4135 
110. Andela, V. B., and Rosier, R. N. (2004) Molecular cancer. 3(1), 8 
111. Koumura, H., Sugiyama, Y., Kunieda, K., and Saji, S. (1997) Gan to kagaku 
ryoho. Cancer & chemotherapy. 24 Suppl 2, 324-331 
112. Tomita, T., and Iwata, K. (1996) Diseases of the colon and rectum. 39(11), 
1255-1264 
113. Emmert-Buck, M. R., Roth, M. J., Zhuang, Z., Campo, E., Rozhin, J., 
Sloane, B. F., Liotta, L. A., and Stetler-Stevenson, W. G. (1994) American 
journal of pathology. 145(6), 1285-1290 
114. Okada, N., Ishida, H., Murata, N., Hashimoto, D., Seyama, Y., and Kubota, 
S. (2001) Biochemical and biophysical research communications. 288(1), 212-
216 
115. Jeziorska, M., Haboubi, N. Y., Schofield, P. F., Ogata, Y., Nagase, H., and 
Woolley, D. E. (1994) International journal of colorectal disease. 9(3), 141-148 
116. Martin, D. C., Rüther, U., Sanchez-Sweatman, O. H., Orr, F. W., and 
Khokha, R. (1996) Oncogene. 13(3), 569-576 
117. Khokha, R. (1994) Journal of the National Cancer Institute. 86(4), 299-304 
118. Ikenaka, Y., Yoshiji, H., Kuriyama, S., Yoshii, J., Noguchi, R., Tsujinoue, H., 
Yanase, K., Namisaki, T., Imazu, H., Masaki, T., and Fukui, H. (2003) 
International journal of cancer. Journal international du cancer. 105(3), 340-
346 
119. Zeng, Z. S., Cohen, A. M., Zhang, Z. F., Stetler-Stevenson, W., and Guillem, 
J. G. (1995) Clinical cancer research: an official journal of the American 
Association for Cancer Research. 1(8), 899-906 
120. Mimori, K., Mori, M., Shiraishi, T., Fujie, T., Baba, K., Haraguchi, M., Abe, 
R., Ueo, H., and Akiyoshi, T. (1997) British journal of cancer. 76(4), 531-536 
 130
121. Fong, K. M., Kida, Y., Zimmerman, P. V., and Smith, P. J. (1996) Clinical 
cancer research: an official journal of the American Association for Cancer 
Research. 2(8), 1369-1372 
122. Kossakowska, A. E., Urbanski, S. J., and Edwards, D. R. (1991) Blood. 
77(11), 2475-2481 
123. Bertaux, B., Hornebeck, W., Eisen, A. Z., and Dubertret, L. (1991) The 
Journal of investigative dermatology. 97(4), 679-685 
124. Chesler, L., Golde, D. W., Bersch, N., and Johnson, M. D. (1995) Blood. 
86(12), 4506-4515 
125. Yamashita, K., Suzuki, M., Iwata, H., Koike, T., Hamaguchi, M., Shinagawa, 
A., Noguchi, T., and Hayakawa, T. (1996) FEBS letters. 396(1), 103-107 
126. Hornebeck, W. (2003) Pathologie-biologie. 51(10), 569-573 
127. Barille, S., Bataille, R., Rapp, M. J., Harousseau, J. L., and Amiot, M. (1999) 
The Journal of immunology: official journal of the American Association of 
Immunologists. 163(10), 5723-5728 
128. Ohta, S., Lai, E. W., Pang, A. L., Brouwers, F. M., Chan, W. Y., Eisenhofer, 
G., de Krijger, R., Ksinantova, L., Breza, J., Blazicek, P., Kvetnansky, R., 
Wesley, R. A., and Pacak, K. (2005) International journal of cancer. Journal 
international du cancer. 114(1), 139-143 
129. Yuan, H., Kamata, M., Xie, Y. M., and Chen, I. S. (2004) Journal of virology. 
78(15), 8183-8190 
130. American, C. S. (2005) Cancer Facts and Figures. pp. 12-14, American 
Cancer Society, Atlanta 
131. Weinzweig, J., Tattini, C., Lynch, S., Zienowicz, R., Weinzweig, N., 
Spangenberger, A., and Edstrom, L. (2003) Plast Reconstr Surg 112(1), 152-
161 
132. Liu, H., Zang, C., Fenner, M. H., Possinger, K., and Elstner, E. (2003) Breast 
Cancer Res Treat 79(1), 63-74 
133. Wu, Q., Chen, Y. Q., Chen, Z. M., Chen, F., and Su, W. J. (2002) Acta 
Pharmacol Sin 23(9), 835-841 
134. Adachi, Y., Itoh, F., Yamamoto, H., Iku, S., Matsuno, K., Arimura, Y., and 
Imai, K. (2001) Tumour Biol 22(4), 247-253 
 131
135. Garcia-Alonso, I., Palomares, T., Alonso-Varona, A., Castro, B., Del Olmo, 
M., Portugal, V., and Mendez, J. (2005) Rev Esp Enferm Dig 97(4), 240-248 
136. Heukamp, I., Kilian, M., Gregor, J. I., Neumann, A., Jacobi, C. A., Guski, H., 
Schimke, I., Walz, M. K., and Wenger, F. A. (2005) Pancreatology 5(4-5), 
403-409 
137. Keely, P. J., Westwick, J. K., Whitehead, I. P., Der, C. J., and Parise, L. V. 
(1997) Nature 390(6660), 632-636 
138. Shaw, L. M., Rabinovitz, I., Wang, H. H., Toker, A., and Mercurio, A. M. 
(1997) Cell 91(7), 949-960 
139. Phillips, W. A., St Clair, F., Munday, A. D., Thomas, R. J., and Mitchell, C. 
A. (1998) Cancer 83(1), 41-47 
140. Uruno, A., Sugawara, A., Kanatsuka, H., Kagechika, H., Saito, A., Sato, K., 
Kudo, M., Takeuchi, K., and Ito, S. (2005) Circulation 112(5), 727-736 
141. Lopez-Carballo, G., Moreno, L., Masia, S., Perez, P., and Barettino, D. 
(2002) J Biol Chem 277(28), 25297-25304 
142. Farias, E. F., Marzan, C., and Mira-y-Lopez, R. (2005) Oncogene 24(9), 1598-
1606 
143. Day, R. M., Lee, Y. H., Park, A. M., and Suzuki, Y. J. (2006) Am J Respir Cell 
Mol Biol 34(6), 695-703 
144. Park, E. Y., Wilder, E. T., and Lane, M. A. (2007) Nutr Cancer 57(1), 66-77 
145. Nguyen, K. T., Wang, W. J., Chan, J. L., and Wang, L. H. (2000) Oncogene 
19(47), 5385-5397 
146. Dillard, A. C., and Lane, M. A. (2007) Mol Carcinog 46(4), 315-329 
147. Fruman, D. A., Rameh, L. E., and Cantley, L. C. (1999) Cell 97(7), 817-820 
148. Doi M, I. T., Terashima A, Taniguchi T, Sasaki M, Tanaka C. (1998) Anal 
Sci 14, 1191-1192 
149. Wymann, M. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., 
Vanhaesebroeck, B., Waterfield, M. D., and Panayotou, G. (1996) Mol Cell 
Biol 16(4), 1722-1733 
150. Pan, J., Kao, Y. L., Joshi, S., Jeetendran, S., Dipette, D., and Singh, U. S. 
(2005) J Neurochem 93(3), 571-583 
 132
151. Antonyak, M. A., McNeill, C. J., Wakshlag, J. J., Boehm, J. E., and Cerione, 
R. A. (2003) J Biol Chem 278(18), 15859-15866 
152. Marchisio, M., Bertagnolo, V., Colamussi, M. L., Capitani, S., and Neri, L. 
M. (1998) Biochem Biophys Res Commun 253(2), 346-351 
153. Bertagnolo, V., Brugnoli, F., Marchisio, M., Celeghini, C., Carini, C., and 
Capitani, S. (2004) Cell Signal 16(4), 423-433 
154. Bertagnolo, V., Neri, L. M., Marchisio, M., Mischiati, C., and Capitani, S. 
(1999) Cancer Res 59(3), 542-546 
155. Ozpolat, B., Akar, U., Steiner, M., Zorrilla-Calancha, I., Tirado-Gomez, M., 
Colburn, N., Danilenko, M., Kornblau, S., and Berestein, G. L. (2007) Mol 
Cancer Res 5(1), 95-108 
156. Gianni, M., Kopf, E., Bastien, J., Oulad-Abdelghani, M., Garattini, E., 
Chambon, P., and Rochette-Egly, C. (2002) J Biol Chem 277(28), 24859-
24862 
157. del Rincon, S. V., Rousseau, C., Samanta, R., and Miller, W. H., Jr. (2003) 
Oncogene 22(22), 3353-3360 
158. Bastien, J., Plassat, J. L., Payrastre, B., and Rochette-Egly, C. (2006) 
Oncogene 25(14), 2040-2047 
159. Nicke, B., Kaiser, A., Wiedenmann, B., Riecken, E. O., and Rosewicz, S. 
(1999) Biochem Biophys Res Commun 261(3), 572-577 
160. Nicke, B., Riecken, E. O., and Rosewicz, S. (1999) Gut 45, 51-57 
161. Lee, M. O., and Kang, H. J. (2002) Biol Pharm Bull 25(10), 1298-1302 
162. Park, E. Y., Dillard, A., Williams, E. A., Wilder, E. T., Pepper, M. R., and 
Lane, M. A. (2005) Cancer Res 65(21), 9923-9933 
163. Pruitt, K., Zinn, R. L., Ohm, J. E., McGarvey, K. M., Kang, S. H., Watkins, 
D. N., Herman, J. G., and Baylin, S. B. (2006) PLoS Genet 2(3), e40 
164. Mills, G. B., Kohn, E., Lu, Y., Eder, A., Fang, X., Wang, H., Bast, R. C., 
Gray, J., Jaffe, R., and Hortobagyi, G. (2003) Semin Oncol 30(5 Suppl 16), 
93-104 
165. Kobayashi, H., Suzuki, M., Kanayama, N., and Terao, T. (2004) J Biol Chem 
279(8), 6371-6379 
 133
166. Huang, Q., Shen, H. M., and Ong, C. N. (2005) Cell Mol Life Sci 62(10), 1167-
1175 
167. Nakashio, A., Fujita, N., and Tsuruo, T. (2002) Int J Cancer 98(1), 36-41 
168. Stephens, L., Williams, R., and Hawkins, P. (2005) Curr Opin Pharmacol 
5(4), 357-365 
169. Fresno Vara, J. A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., and 
Gonzalez-Baron, M. (2004) Cancer Treat Rev 30(2), 193-204 
170. Stoyanova, S., Bulgarelli-Leva, G., Kirsch, C., Hanck, T., Klinger, R., 
Wetzker, R., and Wymann, M. P. (1997) Biochem J 324 (Pt 2), 489-495 
171. West, K. A., Castillo, S. S., and Dennis, P. A. (2002) Drug Resist Updat 5(6), 
234-248 
172. Gout, S., Tremblay, P. L., and Huot, J. (2007) Clin Exp Metastasis  
173. Heukamp, I., Kilian, M., Gregor, J., Neumann, A., Jacobi, C., Guski, H., 
Schimke, I., Walz, M., and Wenger, F. (2005) Pancreatology 5, 403-409 
174. Park, E. Y., Wilder, E. T., Chipuk, J. E., and Lane, M. A. (2007) Mol 
Carcinog  
175. Ozawa, S., Shinohara, H., Kanayama, H. O., Bruns, C. J., Bucana, C. D., 
Ellis, L. M., Davis, D. W., and Fidler, I. J. (2001) Neoplasia 3(2), 154-164 
176. Rychahou, P. G., Jackson, L. N., Silva, S. R., Rajaraman, S., and Evers, B. 
M. (2006) Ann Surg 243(6), 833-842; discussion 843-834 
177. National Research Council. (1995) Nutrient Requirements of Laboratory 
Animals, National Academy Press, Washington, DC 
178. Wildi, S., Kleeff, J., Maruyama, H., Maurer, C. A., Friess, H., Buchler, M. 
W., Lander, A. D., and Korc, M. (1999) Clin Cancer Res 5(10), 2840-2847 
179. Food and Nutrition Board. (2000) Dietary Reference Intakes for Vitamin A, 
Vitamin K, Arsenic, Boron, Chrominum, Copper, Iodine. Iron, Manganese, 
Molybdenum, Nikel, Silico n, Vanadium, and Zinc, National Academy Press, 
Washington DC. 
180. Penniston, K., and Tanumihardjo, S. (2006) Am J Clin Nutr 83, 191-201 
181. Hathcock, J. N. (1997) Am J Clin Nutr 66(2), 427-437 
 134
182. Council, N. R. (1995) Nutrient Requirements of Laboratory Animals, National 
Academy Press, Washington, DC 
183. Khaleghpour, K., Li, Y., Banville, D., Yu, Z., and Shen, S. H. (2004) 
Carcinogenesis 25(2), 241-248 
184. Roy, H. K., Olusola, B. F., Clemens, D. L., Karolski, W. J., Ratashak, A., 
Lynch, H. T., and Smyrk, T. C. (2002) Carcinogenesis 23(1), 201-205 
185. Samuels, Y., Diaz, L. A., Jr., Schmidt-Kittler, O., Cummins, J. M., Delong, 
L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., 
Vogelstein, B., and Velculescu, V. E. (2005) Cancer Cell 7(6), 561-573 
186. Bruzek, L. M., Poynter, J. N., Kaufmann, S. H., and Adjei, A. A. (2005) Mol 
Pharmacol 68(2), 477-486 
187. Park, C. M., Park, M. J., Kwak, H. J., Lee, H. C., Kim, M. S., Lee, S. H., 
Park, I. C., Rhee, C. H., and Hong, S. I. (2006) Cancer Res 66(17), 8511-8519 
188. Xie, Z., Yuan, H., Yin, Y., Zeng, X., Bai, R., and Glazer, R. I. (2006) BMC 




Eunyoung Park was born in Seoul, Korea on November 8, 1976 to Yong Jun 
Park, and Sun Hee Hwang.  She has two younger sisters, Jin Young Park and Ha Young 
Park.  She received her Bachelor of Science in Department of Bioscience and 
Biotechnology from the Hankuk University of Foreign Study in February 2000 and her 
Master of Science in School of Biological Sciences from the Seoul National University in 
February 2002.  She began her graduate work at the University of Texas at Austin in 
August 2003. 
 
Permanent Address: 253-2 JOOBOOK-RI, YANGJI-MYEON, YONGIN, KYONGGI-
DO, KOREA, 449-822 
This dissertation was typed by Eunyoung Park 
